

**(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

**(19) World Intellectual Property Organization**  
International Bureau



**(43) International Publication Date**  
17 January 2002 (17.01.2002)

**PCT**

**(10) International Publication Number**  
**WO 02/04448 A2**

**(51) International Patent Classification<sup>7</sup>:** **C07D 473/00**

**(21) International Application Number:** PCT/US01/21373

**(22) International Filing Date:** 6 July 2001 (06.07.2001)

**(25) Filing Language:** English

**(26) Publication Language:** English

**(30) Priority Data:**  
60/216,844 7 July 2000 (07.07.2000) US

**(71) Applicant** (for all designated States except US):  
**NEOTHERAPEUTICS, INC.** [US/US]; 157 Technology Drive, Irvine, CA 92618 (US).

**(72) Inventors; and**

**(75) Inventors/Applicants** (for US only): **DIAMOND, Jack** [CA/CA]; 25 Chedoke Avenue Lane, Hamilton, Ontario L8P 4S1 (CA). **GLASKY, Alvin, J.** [US/US]; 11955 Lambert, Tustin, CA 92782 (US).

**(74) Agents:** **CULLMAN, Louis, C.** et al.; Oppenheimer Wolff & Donnelly LLP, Suite 700, 840 Newport Center Drive, Newport Beach, CA 92660-7007 (US).


**(81) Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 02/04448 A2**

**(54) Title:** METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS

**(57) Abstract:** A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. Methods according to the present invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.

**METHODS FOR TREATMENT OF DRUG-INDUCED  
PERIPHERAL NEUROPATHY AND RELATED CONDITIONS**

**CROSS-REFERENCES**

This application claims priority from Provisional Application Serial No.

5 60/216,844, filed July 7, 2000 by Jack Diamond and Alvin J. Glasky, and entitled "Methods for Treatment of Peripheral Neuropathy and Related Conditions with Bifunctional Purine Analogues," which is incorporated herein in its entirety by this reference.

**BACKGROUND OF THE INVENTION**

10 This invention is directed to methods for treatment of drug-induced peripheral neuropathy and related conditions, particularly drug-induced peripheral neuropathy associated with the administration of oncolytic drugs.

Many oncolytic or antineoplastic drugs have been developed in recent years. Although such drugs have proven effective in many cases in the treatment of 15 malignancies, they can have severe side effects. One of the most serious and clinically significant side effect is peripheral neuropathy. Many antineoplastic drugs can cause peripheral neuropathy. For some of the most effective drugs, neurotoxicity is dose-limiting. It can force the termination of otherwise successful therapy, or can preclude the repetition of successful therapy. Sensory abnormalities produced by the 20 administration of antineoplastic drugs can range from mild paresthesiae or dysesthesiae to severe neuropathic pain. In some cases, sensory and motor symptoms resolve within days or weeks after the agents are discontinued. However, peripheral neuropathy can be a chronic painful and disabling condition. The mechanisms that produce peripheral neuropathy as a consequence of the 25 administration of oncolytic drugs are largely unknown (R.C. Polomano & G.J. Bennett, "Chemotherapy-evoked Painful Peripheral Neuropathy," Pain Med. 2: 8-14 (2001); S. De Santis et al., "Patients Treated with Antitumor Drugs Displaying Neurological Deficits Are Characterized by a Low Circulating Level of Nerve Growth Factor," Clin. Cancer Res. 6: 90-95 (2000); K. Hayakawa et al., "NGF Prevention of Neurotoxicity 30 Induced by Cisplatin, Vincristine and Taxol Depends on Toxicity of Each Drug and NGF Treatment Schedule: In Vitro Study of Adult Rat Sympathetic Ganglion Explants," Brain Res. 794: 313-319 (1998)).

Accordingly, there is a need for more efficient methods of combating drug-induced peripheral neuropathy, particularly peripheral neuropathy induced by the administration of oncolytic drugs. Preferably, such methods should not interfere with cancer treatment or block the activity of the oncolytic drugs. Such methods should 5 also not induce other side effects and should be well tolerated by cancer patients. Preferably, such methods should also combat peripheral neuropathy for all oncolytic drugs and should not depend on specific interactions with each individual oncolytic drug. There is a particular need for methods that can stimulate nerve growth or regeneration, particularly without inducing hyperalgesia.

## 10 **SUMMARY**

One embodiment of the present invention is a method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of an effective quantity of a compound comprising: (1) a moiety A selected from the group consisting of a purine moiety, a 15 purine analogue, a tetrahydroindolone moiety, a tetrahydroindolone analogue, a pyrimidine moiety, a pyrimidine analogue and aminocarboxaminoimidazoles; (2) a hydrocarbyl moiety L of 1 to 6 carbon atoms that is linked to the moiety A and that can be cyclic, with the hydrocarbyl moiety being optionally substituted with one or more substituents selected from the group consisting of lower alkyl, amino, hydroxy, lower 20 alkoxy, lower alkylamino, lower alkylthio, and oxo; and (3) a moiety B that is linked to the moiety L through a carbonyl group wherein B is  $-OZ$  or  $N(Y_1)-D$ , where Z is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, or heteroaralkyl; D is a moiety that promotes absorption of the compound; and  $Y_1$  is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, 25 alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms, which 30 can be N, O, or S.

The purine moiety can be selected from the group consisting of hypoxanthine and guanine, as well as other purine moieties. A number of purine derivatives suitable for use in methods according to the present invention are disclosed. In addition to

these purines, analogues of naturally occurring purines defined above, tetrahydroindolones, tetrahydroindolone analogues, pyrimidines, pyrimidine analogues and aminocarboxaminoimidazoles, which maintain the proposed pharmacophore between the 6, 5, 4, and 9 positions on the purine molecule, may be 5 used as alternatives to purines.

Preferably, the compound is capable of passing through the blood-brain barrier.

Typically, the administration of the compound induces peripheral nerve sprouting in the skin of the patient to whom the purine derivative is administered. The peripheral nerve sprouting can be nociceptive nerve sprouting. Typically, the 10 nociceptive nerve sprouting is induced without the occurrence of hyperalgesia.

The drug-induced peripheral neuropathy can be induced by the administration of an oncolytic drug such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. Methods 15 according to the present invention are particularly significant in treating drug-induced peripheral neuropathy arising from the administration of vincristine, paclitaxel, or cisplatin.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

The following invention will become better understood with reference to the 20 specification, appended claims, and accompanying drawings, where:

Figure 1 is a bar graph showing the effects of riluzole and AIT-082 in the prevention of cisplatin toxicity in DRG cells;

Figure 2 is a graph showing the effects of vincristine or vincristine plus AIT-082 on body weight;

25 Figure 3 is a bar graph showing sensory nerve conduction velocity demonstrating the effects of AIT-082 on vincristine-induced neuropathy;

Figure 4 is a bar graph showing EMG amplitude demonstrating the effects of AIT-082 on vincristine-induced neuropathy;

30 Figure 5 is a bar graph showing the effect of AIT-082 on the total number of myelinated nerve fibers after vincristine administration.

## DESCRIPTION

We have discovered that the bifunctional purine derivative N-4-carboxyphenyl-3-(6-oxohypoxanthine-9-yl) propanamide (also known as AIT-082 and letepirinim potassium), which bypasses the blood-brain barrier, can act to induce peripheral nerve sprouting in the skin of adult rats. As detailed below in the Example, this activity may be attributable to upregulation of cutaneous nerve growth factor (NGF) levels induced by this bifunctional purine derivative, although Applicants do not intend to be bound by this theory. Moreover, this activity occurred without the induction of hyperalgesia. This property of acting to induce peripheral nerve sprouting, therefore, should also be possessed by other purine derivatives and analogues, tetrahydroindolone derivatives and analogues, and pyrimidine derivatives and analogues, as discussed below.

The peripheral nerve sprouting can be nociceptive nerve sprouting. The nociceptive nerve sprouting can occur without the induction of hyperalgesia.

Typically, a compound useful in a method of the present invention is capable of bypassing the blood-brain barrier.

More specifically, as detailed below in the Example, systematically administered AIT-082 closely mimics the effects both of increased levels of endogenous NGF, and of exogenous NGF. The compound induces vigorous collateral sprouting but has no effect on axonal regeneration after nerve crush (shown earlier to occur independently of NGF), and the sprouting it induced was blocked by systemic anti-NGF treatment. The growth of such nerve tissue is evoked and maintained entirely by the increased levels of NGF in adjacent denervated skin. However, AIT-082 resembles more the effects of increased endogenous NGF than of exogenous NGF, because it did not induce hyperalgesia. In fact, the sprouting evoked by AIT-082 was shown to be entirely attributable to the measured up-regulation it induced in endogenous NGF levels in skin.

Accordingly, one aspect of the present invention is a method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of a compound, the compound comprising:

(1) a moiety A selected from the group consisting of a purine moiety, a purine analogue, a tetrahydroindolone moiety, a tetrahydroindolone analogue, a pyrimidine moiety, and a pyrimidine analogue; (2) a hydrocarbyl moiety L of 1 to 6 carbon atoms that is linked to the moiety A and that can be cyclic, with the hydrocarbyl moiety being optionally substituted with one or more substituents selected from the group consisting

of lower alkyl, amino, hydroxy, lower alkoxy, lower alkylamino, lower alkylthio, and oxo; and (3) a moiety B that is linked to the moiety L though a carbonyl group wherein B is  $-OZ$  or  $N(Y_1)-D$ , where Z is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, or heteroaralkyl; D is a moiety that promotes absorption of the compound having activity

5 against a multi-drug transporter protein; and  $Y_1$  is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl,  
10 heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms, which can be N, O, or S.


Typically, a compound useful in a method of the present invention is capable of passing through the blood-brain barrier.

15 In one preferred embodiment of methods according to the present invention, the moiety A is a purine moiety.

In one alternative, A is a substituted or unsubstituted hypoxanthine moiety.

Typically, in this alternative, L has the structure  $-(CH_2)_n$  where n is an integer from 1 to 6.


20 The compound having the activity against drug-induced peripheral neuropathy  
can be a compound of formula (I)



where n is an integer from 1 to 6 and R is hydrogen or lower alkyl or is a salt or prodrug ester of a compound of formula (I) wherein n is an integer from 1 to 6 and R is hydrogen or lower alkyl. Typically, the compound is a compound of formula (I) wherein n is an integer from 1 to 6 and R is hydrogen or lower alkyl. Typically, R is hydrogen, and the compound is N-4-[[3-(6-oxo-1,6-dihydropurin-9-yl)-1-oxopropyl]

amino] benzoic acid, designated AIT-082. Alternatively, R is ethyl, and the compound is N-4-[[3-(6-oxo-1,6-dihydropurin-9-yl)-1-oxopropyl] amino] benzoic acid ethyl ester.

When the purine moiety is hypoxanthine, a preferred purine derivative is a compound of formula (I)




5

(I)

wherein n is an integer from 1 to 6 or of a salt or prodrug ester of formula (I) wherein n is an integer from 1 to 6. Typically, the purine derivative is a compound of formula (I) wherein n is an integer from 1 to 6. Preferably, n is 2 and the compound is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl) propanamide, also known as AIT-082. The

10 activity of this compound is described further in the Example.

Alternatively, the purine derivative can be a 9-substituted hypoxanthine derivative of formula (II)



(II)


wherein n is a integer from 1 to 6, R<sub>1</sub> is selected from the group consisting of H,

15 COOH, and COOW<sub>1</sub>, where W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, and R<sub>2</sub> is selected from the group consisting of H and OH.

In this alternative, for one particularly preferred purine derivative, n is 2, R<sub>1</sub> is H and R<sub>2</sub> is OH and the purine derivative is N-(2-(5-hydroxyindol-3-yl))ethyl-3-(6-

oxohypoxanthine-9-yl) propanamide. In this alternative, for another particularly preferred purine derivative, n is 2, R<sub>1</sub> is H and R<sub>2</sub> is H and the purine derivative is N-(2-indol-3-yl)ethyl-3-(6-oxohypoxanthine-9-yl) propanamide. In this alternative, for still another particularly preferred purine derivative, n is 2, R<sub>1</sub> is COOH, and R<sub>2</sub> is OH and the purine derivative is N-(1-carboxyl-(2-(5-hydroxyindol-3-yl))ethyl-3-(6-oxohypoxanthine-9-yl) propanamide.


As another alternative, the purine derivative can be a 9-substituted hypoxanthine derivative of formula (III)



wherein n is an integer from 1 to 6, R<sub>1</sub> is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, wherein W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, R<sub>2</sub> is selected from the group consisting of H and OH, and R<sub>3</sub> is selected from the group consisting of H and OH.

In this alternative, for one particularly preferred purine derivative, n is 2, R<sub>1</sub> is H, R<sub>2</sub> is H, and R<sub>3</sub> is OH, and the purine derivative is N-(2-(3,4-dihydroxyphenyl))ethyl-3-(6-oxohypoxanthine-9-yl) propanamide. In this alternative, for another particularly preferred purine derivative, n is 2, R<sub>1</sub> is H, R<sub>2</sub> is OH, and R<sub>3</sub> is OH, and the purine derivative is N-(2-hydroxy-2-(3,4-dihydroxyphenyl))ethyl-3-(6-oxohypoxanthine-9-yl) propanamide. In this alternative, for still another particularly preferred purine derivative, n is 2, R<sub>1</sub> is COOH, R<sub>2</sub> is H, and R<sub>3</sub> is OH, and the purine derivative is N-(1-carboxyl-2-(3,4-dihydroxyphenyl))ethyl-3-(6-oxohypoxanthine-9-yl) propanamide.

When the purine moiety is guanine, one preferred purine derivative is a 9-substituted guanine derivative of formula (IV)




(IV)

wherein n is an integer from 1 to 6, R<sub>1</sub> is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, or W<sub>1</sub> is lower alkyl, amino, or lower alkylamino, and R<sub>2</sub> is selected from the group consisting of H and OH.

5 In this alternative, for one particularly preferred purine derivative, n is 2, R<sub>1</sub> is H, and R<sub>2</sub> is OH, and the purine derivative is N-(2-(5-hydroxindol-3-yl))ethyl-3-(2-amino-6-oxohydropurin-9-yl) propanamide. In this alternative, for another particularly preferred purine derivative, n is 2, R<sub>1</sub> is H, and R<sub>2</sub> is H and the purine derivative is N-(2-(2-indol-3-yl)ethyl)-3-(2-amino-6-oxohydropurin-9-yl) propanamide. In this alternative, for still 10 another particularly preferred purine derivative, n is 2, R<sub>1</sub> is COOH, and R<sub>2</sub> is OH, and the purine derivative is N-(1-carboxyl)-(2-(5-hydroxyindol-3-yl))ethyl-3-(2-amino-6-oxohydropurin-9-yl) propanamide.


Alternatively, the purine derivative can be a 9-substituted guanine derivative of formula (V) wherein n is an integer from 1 to 6.



(V)

In this alternative, for one particularly preferred purine derivative, n is 2 and the compound is N-4-carboxyphenyl-3-(2-amino-6-oxohydropurin-9-yl) propanamide.


Alternatively, the purine derivative can be a 9-substituted guanine derivative of formula (VI) wherein n is an integer from 1 to 6.



(VI)

In this alternative, for one particularly preferred purine derivative,  $n$  is 2 and the compound is 3-(2-amino-6-oxohdropurine-9-yl) propanoic acid.


Alternatively, the purine derivative can be a 9-substituted guanine derivative of 5 formula (VII) wherein  $n$  is an integer from 1 to 6,  $p$  is an integer from 1 to 6, and  $q$  is an integer from 1 to 3.



(VII)

In this alternative, for one particularly preferred purine derivative,  $n$  is 2,  $p$  is 2, and  $q$  is 1, and the purine derivative is  $\text{N}-[2-[(2-\text{oxopyrrolidin-1-yl})-1-$  10  $\text{oxoethyl}]amino]ethyl] propanamide.$

Alternatively, the purine derivative can be a 9-substituted guanine derivative of formula (VIII) wherein  $R_1$  is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, where W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, R<sub>2</sub> is selected from the group consisting of H and OH, and R<sub>3</sub> is 15 selected from the group consisting of H and OH.




(VIII)

In this alternative, for one particularly preferred purine derivative,  $n$  is 2,  $R_1$  is H,  $R_2$  is H, and  $R_3$  is OH, and the purine derivative is  $\text{N}-(2-(3,4-\text{dihydroxyphenyl})ethyl-3-$

(2-amino-6-oxohypoxanthine-9-yl) propanamide. In this alternative, for another particularly preferred purine derivative, n is 2, R<sub>1</sub> is H, R<sub>2</sub> is OH, and R<sub>3</sub> is OH, and the purine derivative is N-(2-hydroxy-2-(3,4-dihydroxyphenyl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide. In this alternative, for still another particularly preferred purine derivative, n is 2, R<sub>1</sub> is COOH, R<sub>2</sub> is H, and R<sub>3</sub> is H and the compound is N-(1-carboxyl-2-(3,4-dihydroxyphenyl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.


5 Alternatively, the purine derivative can be a 9-substituted guanine derivative of formula (IX) wherein n is an integer from 1 to 6 and p is an integer from 1 to 3.



In this alternative, for one particularly preferred purine derivative, n is 2, p is 1, and the compound is the 1-(dimethylamino)-2-propyl ester of N-4-carboxyphenyl-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

15 Other bifunctional hypoxanthine derivatives suitable for use in methods according to the present invention are disclosed in U.S. Patent No. 5,091,432 to Glasky, incorporated herein by this reference. Other bifunctional guanine derivatives suitable for use in methods according to the present invention are disclosed in U.S. Patent Application No. 09/49,153, by Glasky et al., incorporated herein by this reference.

20 More generally, purine-based compounds suitable for use in methods according to the present invention are compounds in which A is a substituted or unsubstituted 9-atom bicyclic moiety in which the 5-membered ring has 1 to 3 nitrogen atoms, the bicyclic moiety having the structure of formula (X)



where:

(1) if the bond between N<sub>1</sub> and the bond between C<sub>5</sub> is a single bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a double bond, R<sub>6</sub> is O or S, and R<sub>1</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, or heteroaralkyl;

(2) if the bond between N<sub>1</sub> and C<sub>6</sub> is a double bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a single bond, R<sub>1</sub> is not present, and R<sub>6</sub> is hydrogen, halo, amino, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl,

10 heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further

15 substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, aralkoxy carbonyl, heteroaralkoxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,

20 aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(3) if the bond between C<sub>2</sub> and N<sub>3</sub> is a single bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a double bond, R<sub>2</sub> is O or S, and R<sub>3</sub> is hydrogen or alkyl;

(4) if the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond, then the bond between C<sub>2</sub> is a single bond, R<sub>3</sub> is not present, and R<sub>2</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo, amino, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl,


aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered  
5 ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl,  
10 alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(5) A<sub>7</sub> and A<sub>8</sub> are C or N;

(a) if A<sub>7</sub> and A<sub>8</sub> are both C and the bond between A<sub>7</sub> and A<sub>8</sub> is a single bond, then the bond between A<sub>8</sub> and R<sub>8</sub> is two single bonds to two hydrogen atoms or is a double bond in which R<sub>8</sub> is O or S and R<sub>7</sub> is two hydrogen atoms;  
15 (b) if A<sub>7</sub> and A<sub>8</sub> are both C and the bond between A<sub>7</sub> and A<sub>8</sub> is a double bond, then R<sub>7</sub> is hydrogen, the bond between A<sub>8</sub> and R<sub>8</sub> is a single bond and R<sub>8</sub> is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or  
20 heteroaralkenyl;  
(c) if A<sub>7</sub> and A<sub>8</sub> are both N, then the bond between A<sub>7</sub> and A<sub>8</sub> is a double bond, and R<sub>7</sub> and R<sub>8</sub> are not present;  
(d) if A<sub>7</sub> is C and A<sub>8</sub> is N, then the bond between A<sub>7</sub> and A<sub>8</sub> is a double bond, R<sub>7</sub> is hydrogen, and R<sub>8</sub> is not present;  
25 (e) if A<sub>7</sub> is N, A<sub>8</sub> is C, and the bond between A<sub>7</sub> and A<sub>8</sub> is a double bond, then R<sub>7</sub> is not present, the bond between A<sub>8</sub> is a single bond, and R<sub>8</sub> is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;  
(f) if A<sub>7</sub> is N, A<sub>8</sub> is C, and the bond between A<sub>7</sub> and A<sub>8</sub> is a single bond, then R<sub>7</sub> is hydrogen, alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, the bond between A<sub>8</sub> and R<sub>8</sub> is a double bond, and R<sub>8</sub> is O or S; and  
30

(6)  $N_9$  is bonded to L; with the proviso that A does not have the structure of an unsubstituted guanine or hypoxanthine.

The purine moiety can be a purine moiety of formula (XI)



5 in which:

- (1)  $R_1$  is selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, and heteroaralkyl; and
- (2)  $R_2$  is selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo,  $OQ_1$ ,  $SQ_1$ ,  $NHNH_2$ ,  $NHOQ_1$ ,  $NQ_1Q_2$ , or  $NHQ_1$ ,

10 where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_1$  and  $Q_2$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered

15 ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylkoxy carbonyl, heteroarylokoxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroarylalkylaminocarbonyl in which the alkyl portions could be cyclic and can contain from one to three heteroatoms which could be N, O, or S, with the proviso that both  $R_1$  and  $R_2$  are not hydrogen and that  $R_1$  is not hydrogen when  $R_2$  is amino.

20

25 The purine moiety of formula (XI) is a hypoxanthine or a guanine derivative but excludes unsubstituted hypoxanthine, in which  $R_1$  and  $R_2$  are hydrogen, and unsubstituted guanine, in which  $R_1$  is hydrogen and  $R_2$  is amino.

In one particularly preferred embodiment,  $R_1$  is butyl and  $R_2$  is hydrogen.

In another preferred embodiment,  $R_1$  is benzyl and  $R_2$  is hydrogen.

30 In another preferred embodiment,  $R_1$  is dimethylaminoethyl and  $R_2$  is hydrogen.

In another preferred embodiment,  $R_1$  is cyclopentyl and  $R_2$  is hydrogen.

In another preferred embodiment, R<sub>1</sub> is cyclohexylmethyl and R<sub>2</sub> is hydrogen.

In another preferred embodiment, R<sub>1</sub> is cyclopropylmethyl and R<sub>2</sub> is hydrogen.

In another preferred embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is phenyl.

In another preferred embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is trifluoromethyl.


5 In another preferred embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is butyl.

In another preferred embodiment, R<sub>1</sub> is butyl and R<sub>2</sub> is butyl.

In another preferred embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is methyl.

In another preferred embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is phenylamino.

Alternatively, the purine moiety is a purine moiety of Formula (XII)



10

in which:

(1) R<sub>2</sub> is selected from the group consisting of hydrogen, halo, amino,

OQ<sub>3</sub>, SQ<sub>3</sub>, NHNH<sub>2</sub>, NHOQ<sub>3</sub>, NQ<sub>3</sub>Q<sub>4</sub>, or NHQ<sub>3</sub>, where Q<sub>3</sub> and Q<sub>4</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl,

15 heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>3</sub> and Q<sub>4</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further

20 substituted with Y<sub>3</sub> where Y<sub>3</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl,

25 aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S; and

(2) R<sub>6</sub> is selected from the group consisting of hydrogen, halo, amino,

OQ<sub>5</sub>, SQ<sub>5</sub>, NHNH<sub>2</sub>, NHOQ<sub>5</sub>, NQ<sub>5</sub>Q<sub>6</sub>, or NHQ<sub>6</sub>, where Q<sub>5</sub> and Q<sub>6</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl,

30 heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1


to 3 heteroatoms which can be N, O, or S, and when Q<sub>5</sub> and Q<sub>6</sub> are present together and are alkyl, they can be taken together to form a 5- or 6- membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, 5 aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylkoxycarbonyl, heteroarylkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl in 10 which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S.

In one preferred example of this embodiment, R<sub>2</sub> is hydrogen and R<sub>6</sub> is -NH<sub>2</sub> or -N(CH<sub>3</sub>)<sub>2</sub>.

In another preferred example of this embodiment, R<sub>2</sub> is hydrogen and R<sub>6</sub> is Cl.

15 In yet another preferred example of this embodiment, R<sub>2</sub> is -NH<sub>2</sub> and R<sub>6</sub> is Cl.

In another alternative, the purine moiety is the purine moiety of Formula (XIII)



in which:


- (1) R<sub>1</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, or heteroaralkyl; and
- 20 (2) R<sub>2</sub> is O or S.

Preferably, in this embodiment, R<sub>1</sub> is hydrogen and R<sub>2</sub> is O or S.

Particularly preferred purine-based compounds for use in methods according to the present invention include: (1) 4-[3-(1-benzyl-6-oxo-1,6-dihydropurin-9-yl)propionylamino] benzoic acid ethyl ester; (2) 4-[3-(1-butyl-6-oxo-1,6-dihydropurin-9-yl)propionylamino] benzoic acid ethyl ester; (3) 4-[3-(1-methyl-6-oxo-1,6-dihydropurin-9-yl)propionylamino] benzoic acid ethyl ester; (4) 4-[3-(1-(2-dimethylaminoethyl)-6-oxo-1,6-dihydropurin-9-yl)propionylamino] benzoic acid ethyl ester; (5) 4-[3-(2,6-dioxo-1,2,3,6-tetrahydropurin-9-yl)propionylamino] benzoic acid ethyl ester; (6) 4-[3-(6-methoxypurin-9-yl)propionylamino] benzoic acid ethyl ester; (7) 4-[3-(6-dimethylaminopurin-9-yl)propionylamino] benzoic acid ethyl ester; (8) 4-[3-(2-amino-6-chloropurin-9-yl)propionylamino] benzoic acid ethyl ester; (9) 4-[2-(6-oxo-2-thioxo-

1,2,3,6-tetrahydropurin-9-yl)propionylamino]benzoic acid ethyl ester; (10) 4-[2-(2-butyl-6-oxo-1,6-dihydropurin-9-yl)propionylamino]benzoic acid ethyl ester; (11) 4-[2-(6-oxo-2-phenyl-1,6-dihydropurin-9-yl)propionylamino]benzoic acid ethyl ester; (12) 4-{{3-(6-chloropurin-9-yl)propionyl}methylamino} benzoic acid methyl ester; (13) 3-(1-benzyl-6-oxo-1,6-dihydropurin-9-yl)-N-[3-(2-oxopyrrolidin-1-yl)propyl] propionamide; (14) 3-(1-benzyl-6-oxo-1,6-dihydropurin-9-yl)-N-{2-[2-(2-oxopyrrolidin-1-yl)acetylamino]ethyl} propionamide; (15) N-3-(2-oxopyrrolidin-1-yl)propyl]-3-(6-oxo-2-thioxo-1,2,3,6-tetrahydropurin-9-yl) propionamide; and (16) 3-(1-benzyl-6-oxo-1,6-dihydropurin-9-yl)-N-(3-morpholin-4-yl-propyl) propionamide.

10 In another alternative of methods according to the present invention, the compound is a tetrahydroindolone derivative or analogue where A is a 9-atom bicyclic moiety in which the 5-membered ring has one to three nitrogen atoms, the bicyclic moiety having the structure of formula (XIV)



15 where:

- (1)  $N_1$  is bonded to L;
- (2)  $A_2$  and  $A_3$  are C or N;

20 (a) If  $A_2$  and  $A_3$  are both C and the bond between  $A_2$  and  $A_3$  is a single bond, then the bond between  $A_2$  and  $R_2$  is two single bonds, two hydrogen atoms or is a double bond in which  $R_2$  is O or S and  $R_3$  is two hydrogen atoms;

(b) If  $A_2$  and  $A_3$  are both C and the bond between  $A_2$  and  $A_3$  is a double bond, then  $R_3$  is hydrogen, the bond between  $A_2$  and  $R_2$  is a single bond and  $R_2$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;

25 (c) If  $A_2$  and  $A_3$  are both N, then the bond between  $A_2$  and  $A_3$  is a double bond and  $R_2$  and  $R_3$  are not present;

(d) If  $A_2$  is N and  $A_3$  is C, then the bond between  $A_2$  and  $A_3$  is a double bond,  $R_2$  is not present, and  $R_3$  is hydrogen;

(e) If  $A_2$  is C,  $A_3$  is N, and the bond between  $A_2$  and  $A_3$  is a double bond, then  $R_3$  is not present, the bond between  $A_2$  and  $R_2$  is a single bond, and  $R_2$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;

5 (f) If  $A_2$  is C,  $A_3$  is N, and the bond between  $A_2$  and  $A_3$  is a single bond, then  $R_3$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, or heteroaralkenyl, the bond between  $A_2$  and  $R_2$  is a double bond, and  $A_2$  is O or S;

(3)  $R_5$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,  $NH_2$ ,  $NHQ_1$ ,  $NQ_1Q_2$ , OH, 10  $OQ_1$ , or  $SQ_1$ , where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, 15 aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_1$  and  $Q_2$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other 20 heteroatom, which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, 25 arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(4)  $R_5'$  is hydrogen unless  $R_5$  is alkyl, in which case  $R_5$  is hydrogen or the same alkyl as  $R_5$ ;

30 (5)  $R_5$  and  $R_5'$  can be taken together as a double bond to  $C_5$ , and can be O, S,  $NQ_3$ , or C which can be substituted with one or two groups  $R_5$ , where  $Q_3$  is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;


(6)  $R_6$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl,  $NH_2$ ,  $NHQ_4$ ,  $NQ_4Q_5$ , OH,  $OQ_4$ , or  $SQ_4$ , where  $Q_4$  and  $Q_5$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_4$  and  $Q_5$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom, which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(7)  $R_6'$  is hydrogen unless  $R_6$  is alkyl, in which case  $R_6'$  is hydrogen or the same alkyl as  $R_6$ ;

(8)  $R_6$  and  $R_6'$  can be taken together as a double bond to  $C_6$  and can be O, S,  $NQ_6$ , or C which can be substituted with one or two groups  $R_5$ , and where  $Q_6$  is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S; and

(9)  $R_7$  is hydrogen unless  $R_5$  is alkyl and  $R_5'$  is hydrogen, in which case  $R_7$  is the same alkyl as  $R_5$ .

Typically, A is a tetrahydroindolone moiety. More typically, the tetrahydroindolone moiety is a tetrahydroindolone moiety of formula (XV)



in which:

(1)  $R_5$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,  $NH_2$ ,  $NH_1$ ,  $NQ_1Q_2$ ,  $OH$ ,  $OQ_1$ , or  $SQ_1$ , where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be

5 cyclic and can contain from one to three heteroatoms which can be N, O, or S;

(2)  $R_5'$  is hydrogen;

(3)  $R_6$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be

10 cyclic and can contain from one to three heteroatoms which can be N, O, or S and where  $W_1$  is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and

15 can contain from one to three heteroatoms which can be N, O, or S;

(4)  $R_6'$  is hydrogen; and


(5)  $R_7$  is hydrogen.

Typically,  $R_5$ ,  $R_5'$ ,  $R_6$ ,  $R_6'$ , and  $R_7$  are all hydrogen.

When A is a tetrahydroindolone moiety, preferred compounds are 4-[3-(4-oxo-

20 4,5,6,7-tetrahydroindolone-1-yl) propionylamino] benzoic acid ethyl ester and 4-[3-(4-oxo-4,5,6,7-tetrahydroindolone-1-yl) propionylamino] benzoic acid.

In another alternative, the compound is a pyrimidine derivative or pyrimidine analogue. In this alternative, A is an amino-substituted 6-membered heterocyclic moiety of formula (XVI)



25

where:

(1) if the bond between  $N_1$  and the bond between  $C_6$  is a single bond, then the bond between  $C_6$  and  $R_6$  is a double bond,  $R_6$  is O or S, and  $R_1$  is hydrogen,

alkyl, aralkyl, cycloalkyl, or heteroaralkyl;

(2) if the bond between N<sub>1</sub> and C<sub>6</sub> is a double bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a single bond, R<sub>1</sub> is not present, and R<sub>6</sub> is hydrogen, halo, amino, OH, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl,

5 heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can 10 contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, 15 alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(3) if the bond between C<sub>2</sub> and N<sub>3</sub> is a single bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a double bond, R<sub>2</sub> is O or S, and R<sub>3</sub> is hydrogen or alkyl;

20 (4) if the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a single bond, R<sub>3</sub> is not present, and R<sub>2</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo, amino, OH, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>3</sub>, where Y<sub>3</sub> is alkyl, aryl, 25 heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>3</sub>, where Y<sub>3</sub> is alkyl, aryl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in 30

which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(5)  $R_4$  is hydrogen, alkyl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl,

5 alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl;

(6)  $A_5$  is carbon or nitrogen;

(7) if  $A_5$  is nitrogen, then  $R_5$  is not present;

(8) if  $A_5$  is carbon, then  $R_5$  is hydrogen, amino, alkyl, alkoxy, halo,

10 nitro, aryl, cyano, alkenyl, or alkaryl;

(9) if  $R_5$  and  $R_6$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl,

15 heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxy carbonyl, heteroaralkoxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which

20 can be N, O, or S; and

(10)  $N_4$  is bonded to L.

Typically,  $A_5$  is carbon and the 6-membered heterocyclic moiety is a pyrimidine moiety.

When A is a pyrimidine moiety, in one alternative,  $R_2$  is O and  $R_3$  is hydrogen.

25 In this alternative, the pyrimidine moiety can be cytosine, thymine, uracil, 3-methyluracil, 3-methylthymine, 4-methylcytosine, 5-methylcytosine, 5-hydroxymethylcytosine, 5-hydroxyuracil, 5-carboxymethyluracil, or 5-hydroxymethyluracil.

In another alternative,  $R_2$  is S and  $R_3$  is hydrogen. In this alternative, the 30 pyrimidine moiety can be 2-thiouracil, 5-methylamino-2-thiouracil, 5-methyl-2-thiouracil, or 2-thiocytosine.

In still another alternative,  $R_2$  is amino and the bond between  $C_2$  and  $N_3$  is a double bond. In this alternative, the pyrimidine moiety can be 2-aminopyrimidinone or 2-amino-4-chloropyrimidinone.

In still another alternative, R<sub>2</sub> is hydrogen and the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond. In this alternative, the pyrimidine moiety can be 4-chloropyrimidine, 5-amino-4-chloropyrimidine, 4-chloro-5-methylpyrimidine, 4-chloro-5-hydroxymethylpyrimidine, or 4-chloro-5-carboxymethylpyrimidine.

5 In still another alternative, R<sub>1</sub> is hydrogen, methyl, or ethyl, R<sub>5</sub> is hydrogen, methyl, or ethyl, and R<sub>6</sub> is O. In this alternative, the pyrimidine moiety can be pyrimidinone.

Particularly preferred pyrimidine compounds include: 4-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 4-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 4-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 4-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid; 4-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid; 4-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid; 3-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 3-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 3-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester; 3-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid; 3-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid; and 3-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

In accordance with the present invention, and as used herein, the following terms, when appearing alone or as part of a moiety including other atoms or groups, are defined with the following meanings, unless explicitly stated otherwise. In addition, all groups described herein can be optionally substituted unless such substitution is excluded. The term "alkyl," as used herein at all occurrences, refers to saturated aliphatic groups including straight-chain, branched-chain, and cyclic groups, all of which can be optionally substituted. Preferred alkyl groups contain 1 to 10 carbon atoms. Suitable alkyl groups include methyl, ethyl, and the like, and can be optionally substituted. The term "alkenyl," as used herein at all occurrences, refers to unsaturated groups which contain at least one carbon-carbon double bond and includes straight-chain, branched-chain, and cyclic groups, all of which can be optionally substituted. Preferable alkenyl groups have 2 to 10 carbon atoms. The term "alkoxy" refers to the ether —O—alkyl, where alkyl is defined as above. The term "aryl" refers to aromatic groups which have at least one ring having a conjugated

$\pi$ -electron system and includes carbocyclic aryl and biaryl, both of which may be optionally substituted. Preferred aryl groups have 6 to 10 carbon atoms. The term "aralkyl" refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl and the like; these groups can be optionally substituted. The term

5 "aralkenyl" refers to an alkenyl group substituted with an aryl group. The term "heteroaryl" refers to carbon-containing 5-14 membered cyclic unsaturated radicals containing one, two, three, or four O, N, or S heteroatoms and having 6, 10, or 14  $\pi$ -electrons delocalized in one or more rings, e.g., pyridine, oxazole, indole, thiazole, isoxazole, pyrazole, pyrrole, each of which can be optionally substituted as discussed

10 above. The term "sulfonyl" refers to the group -S(O<sub>2</sub>)-. The term "alkanoyl" refers to the group -C(O)Rg, where Rg is alkyl. The term "aroyl" refers to the group -C(O)Rg, where Rg is aryl. Similar compound radicals involving a carbonyl group and other groups are defined by analogy. The term "aminocarbonyl" refers to the group -NHC(O)-. The term "oxycarbonyl" refers to the group -OC(O)-. The term

15 "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group. Similarly, the term "heteroaralkenyl" refers to an alkenyl group substituted with a heteroaryl group. As used herein, the term "lower," in reference to an alkyl or the alkyl portion of an another group including alkyl, is defined as a group containing one to six carbon atoms. The term "optionally substituted" refers to one or more substituents that can

20 be lower alkyl, aryl, amino, hydroxy, lower alkoxy, aryloxy, lower alkylamino, arylamino, lower alkylthio, arylthio, or oxo, in some cases, other groups can be included, such as cyano, acetoxy, or halo. The term "halo" refers generally to fluoro, chloro, bromo, or iodo; more typically, "halo" refers to chloro.

As indicated above, the linker L is a hydrocarbyl moiety of 1 to 6 carbon atoms

25 that can be cyclic, with the hydrocarbyl moiety being optionally substituted with one or more substituents selected from the group consisting of lower alkyl, amino, hydroxy, lower alkoxy, lower alkylamino, lower alkylthio, and oxo. Preferably, the linker L has the structure -(CH<sub>2</sub>)<sub>n</sub>- wherein n is an integer from 1 to 6. As detailed below, for most preferred embodiments of compounds useful in methods according to the present


30 invention, a preferred linker has n equal to 2 or 3.

The moiety B is either: (i) -OZ, where Z is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, or heteroaralkyl; or (ii) N(Y<sub>1</sub>)-D, where D is a moiety that promotes absorption of the compound, and Y<sub>1</sub> is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, which, when taken with D, can form a cyclic 5- or 6-membered

saturated ring which can contain one other heteroatom which can be O, N, or S, of which N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroaryl sulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, 5 aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S. Typically,  $Y_1$  is hydrogen. Where the moiety B is  $-OZ$ , the moiety B is a carboxylic acid or 10 carboxylic acid or ester. Typically, where B is a carboxylic acid ester, the moiety Z is a lower alkyl, such as methyl, ethyl, butyl, propyl, or isopropyl.


In one alternative, the moiety D, as described above, is a moiety having at least one polar, charged, or hydrogen-bond-forming group to improve the metabolic and bioavailability properties of the compound. The moiety D can be, but is not limited to, 15 a moiety with physiological or biological activity such as nootropic activity. In one alternative, the moiety D can be a moiety containing at least one carboxyl, carboxamide, carboxyl ester, or carbonyl function. In another alternative, the moiety D can be a moiety containing at least one hydroxyl, primary amino, secondary amino, tertiary amino, sulfhydryl, or sulfonamidyl function. The moiety D can be cyclic or 20 acyclic. Preferred examples of the moiety D are described below.

When the moiety D is a cyclic or acyclic moiety containing at least one carbonyl, carboxamide, carboxyl ester, or carbonyl function, in one preferred example, D is a carboxylic acid or carboxylic acid ester with the structure




25 wherein p is an integer from 1 to 6 and  $W_1$  is selected from the group consisting of hydrogen and lower alkyl. Typically, if  $W_1$  is lower alkyl, it is methyl, ethyl, propyl, butyl, or isobutyl. Typically, p is 3. Typically,  $W_1$  is hydrogen or ethyl.

In another preferred example, D and  $Y_1$  are taken together to form a piperazine derivative as described in D. Manetti et al., "Molecular Simplification of 1,4-Diazabicyclo[4.3.0]nonan-9-ones Gives Piperazine Derivatives That Maintain High Nootropic Activity," *J. Med. Chem.* 43: 4499-4507 ("Manetti et al. (2000)"). B is an analogue of structure



wherein Q<sub>1</sub> is hydrogen, methyl, ethyl, butyl, or propyl, Q<sub>2</sub> is hydrogen or methyl, where, if Q<sub>2</sub> is methyl, it can be located at either of the two possible positions in the piperazine ring.


5 In another preferred example, D has the structure



where one of Z<sub>1</sub> and Z<sub>2</sub> is hydrogen, and the other of Z<sub>1</sub> and Z<sub>2</sub> is -COOH or -COOW<sub>1</sub>, wherein W<sub>1</sub> is alkyl. Typically, W<sub>1</sub> is selected from the group consisting of methyl, ethyl, propyl, butyl, and isobutyl. Either of Z<sub>1</sub> or Z<sub>2</sub> can be hydrogen.


10 When Z<sub>1</sub> is -COOH and Z<sub>2</sub> is -COOH, the moiety B is *p*-aminobenzoic acid (PABA). When Z<sub>1</sub> is -COOH and Z<sub>2</sub> is hydrogen, the moiety B is *m*-aminobenzoic acid (MABA). When Z<sub>1</sub> is hydrogen and Z<sub>2</sub> is -COOW<sub>1</sub>, the moiety B is an ester of *p*-aminobenzoic acid (PABA). When Z<sub>1</sub> is -COOW<sub>1</sub> and Z<sub>2</sub> is hydrogen, the moiety B is an ester of *m*-aminobenzoic acid (MABA). Typically, these esters are ethyl esters.

15 When the moiety D is a moiety that contains at least one hydroxyl, primary amino, secondary amino, tertiary amino, sulfhydryl, or sulfonamidyl function, in one preferred example, D is a phenylsulfonamidyl moiety of structure




wherein p is an integer from 0 to 6. Typically, p is 2.

20 In another preferred example, D is an alkylpyridyl moiety of structure



wherein p is an integer from 1 to 6. Typically, p is 1.


In another preferred example, D is a dialkylaminoalkyl moiety of the structure



wherein p is an integer from 1 to 6 and Q<sub>7</sub> and Q<sub>8</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5 or 6 member ring which may contain 1 other heteroatom which can be N, O, or S, of which the N may be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S.

Where Q<sub>7</sub> and Q<sub>8</sub> can be taken together to form a five or six member ring, the ring is typically pyrrolidine, piperidine, or morpholine. The pyrrolidine ring can be optionally substituted with oxo. The piperidine ring can be optionally substituted with methyl or ethyl. Typically, p is 2 or 3.

In another preferred example, D is an alkylpyrrolidine moiety of the structure



wherein p is an integer from 1 to 6 and W<sub>1</sub> is selected from the group consisting of methyl, ethyl, and propyl. Typically, W<sub>1</sub> is methyl. Typically, p is 2.

Preferably, a compound useful in methods according to the present invention has a log P of from about 1 to about 4 in order to optimize bioavailability and CNS penetration of the compound.

As detailed below in the Example, compounds used in methods according to the present invention are believed to exert their activity through the upregulation of neurotrophic factor synthesis. The upregulation of neurotrophic factor synthesis can involve one or more of these neurotrophic factors: NGF, NT-3, BDNF, and NT-4/5.

Exemplary studies and treatments were performed as discussed below using various dosages and routes of administration of selected exemplary compounds representative of compositions that are effective with the methods of the present invention. Of course, those skilled in the art will recognize that the present invention is

not specifically limited to the particular compositions, dosages or routes of administration detailed below.

Depending upon the particular needs of the individual subject involved, the compositions used in the present invention may be administered in various doses to provide effective treatment concentrations based upon the teachings of the present invention. What constitutes an effective amount of the selected composition will vary based upon such factors including the activity of the selected compound, the physiological characteristics of the subject, the extent and nature of the subject's disease or condition and the method of administration. Exemplary treatment concentrations which have proven effective in modifying neural activity range from less than 1  $\mu$ M to concentrations of 500 mM or more. Generally, initial doses will be modified to determine the optimum dosage for treatment of the particular mammalian subject. The compositions may be administered using a number of different routes including orally, topically, transdermally, intraperitoneal injection or intravenous injection directly into the bloodstream. Of course, effective amounts of the compounds may also be administered through injection into the cerebrospinal fluid or infusion directly into the brain, if desired.

The methods of the present invention may be effected using compounds administered to a mammalian subject either alone or in combination as a pharmaceutical formulation. Further, the compounds may be combined with pharmaceutically acceptable excipients and carrier materials such as inert solid diluents, aqueous solutions or non-toxic organic solvents. If desired, these pharmaceutical formulations may also contain preservatives and stabilizing agents and the like, as well as minor amounts of auxiliary substances such as wetting or emulsifying agents, as well as pH buffering agents and the like which enhance the effectiveness of the active ingredient. The pharmaceutically acceptable carrier can be chosen from those generally known in the art, including, but not limited to, human serum albumin, ion exchangers, dextrose, alumina, lecithin, buffer substances such as phosphate, glycine, sorbic acid, potassium sorbate, propylene glycol, polyethylene glycol, and salts or electrolytes such as protamine sulfate, sodium chloride, or potassium chloride. Other carriers can be used.

Liquid compositions can also contain liquid phases either in addition to or to the exclusion of water. Examples of such additional liquid phases are glycerin, vegetable

oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.

The compositions can be made into aerosol formations (i.e., they can be "nebulized") to be administered via inhalation. Aerosol formulations can be placed into 5 pressurized acceptable propellants, such as dichloromethane, propane, or nitrogen. Other suitable propellants are known in the art.

Formulations suitable for parenteral administration, such as, for example, by intravenous, intramuscular, intradermal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions. These can contain antioxidants, 10 buffers, preservatives, bacteriostatic agents, and solutes that render the formulation isotonic with the blood of the particular recipient. Alternatively, these formulations can be aqueous or non-aqueous sterile suspensions that can include suspending agents, thickening agents, solubilizers, stabilizers, and preservatives. Compositions suitable for use in methods according to the present invention can be administered, for 15 example, by intravenous infusion, orally, topically, intraperitoneally, intravesically, or intrathecally. Formulations of compounds suitable for use in methods according to the present invention can be presented in unit-dose or multi-dose sealed containers, in physical forms such as ampules or vials.

The drug-induced peripheral neuropathy to be treated can be drug-induced 20 peripheral neuropathy induced by the administration of a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, and thioguanine. Vinca alkaloids include vincristine and vinblastine. Peripheral neuropathy associated with the administration of oncolytic drugs is described in C.M. 25 Haskell, "Cancer Treatment" (5<sup>th</sup> Ed., W.B. Saunders, Philadelphia, 2001), ch. 10, pp. 104-214, incorporated herein by this reference. In particular, methods according to the present invention are particularly useful in treating drug-induced peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.

Although Applicants do not intend to be bound by this theory, the beneficial 30 effects of bifunctional purine derivatives such as AIT-082 may depend on generalized trophic and NGF-sensitive mechanisms and not merely on the induction of sprouting. These trophic effects may boost the capacity of NGF-sensitive neurons to respond to still unknown regeneration factors other than NGF itself. For example, it is likely that

CGRP and Substance P expression increases with treatment with AIT-082 or other bifunctional purine derivatives.

The invention is illustrated by the following Examples. These Examples are presented for illustration only and are not intended to limit the invention.

5        EXAMPLE 1

EFFECT OF AIT-082 ON NEUROTOXICITY INDUCED BY CISPLATIN AND VINCERISTINE

METHODS AND MATERIALS

In Vitro Procedures

10        *Culture of dorsal root ganglion neurons.*

The dorsal root ganglion neurons were obtained from rat fetuses (Wistar rats; E15 ; Elevage Janvier, Le Genest St Isle). They were dissected and incubated in trypsin 1X (Gibco; Life Technologies, Cergy-Pontoise, France) for 30 min at 37°C. The reaction was stopped by addition of free Hanks balanced salt solution containing calcium and magnesium ; (HBSS<sup>+</sup> ; Gibco) added with 10 % of fetal bovine serum (FBS ; Gibco) and 0.5 mg/ml DNase I (Boehringer Mannheim, Meylan, France). The suspension was triturated with a 10-ml pipette and using a needle seringe. After centrifugation, the dissociated cells were resuspended in DMEM containing 10 % FBS, 2% of chick embryos extract (Gibco), 1 % antibiotics (Gibco) and NGF (Tébu, Le Perray en Yvelines, France) 3 ng/ml final.

Viable cells were counted and seeded at  $\pm$  50,000 cells /well in 96 well-plates (Nunclon, Life Technologies) coated with poly-L-lysine (0.01 mg/ml, Sigma). Cells were maintained in a humidified incubator at 37°C in 5 % CO<sub>2</sub>-95 % air atmosphere.

After 24h, the culture medium was completed with anti-mitotic compounds (5-fluoro-5'-deoxyuridine and cytosine  $\beta$ -D-arabinofuranoside) and uridine all 10<sup>-5</sup>M final. This treatment is aimed at eliminating contaminating fibroblasts and inhibiting the proliferation of Schwann cells.

Cultures were rinsed 48 hrs later (medium without any growth factors) and medium was replaced with fresh medium (200  $\mu$ l /well) containing cisplatin (3.5 ng/ml ; Sigma) added or not with the reference or test compounds.

After 48 h of intoxication, survival rates were measured using an acid phosphatase enzymatic activity assay.

*Survival rate.*

Acid phosphatase activity was measured according to a previously described method (Ueda et al.; 1994). After removal of the culture medium, wells were rinsed twice with PBS (Life Technologies) and incubated with 100  $\mu$ l of buffer containing 0.1 M sodium acetate (pH5.5), 0.1 % Triton X100 (Sigma) and 10 mM p-nitrophenyl phosphate (Sigma) 1h at 37°C/5% CO<sub>2</sub>. Reaction was stopped by addition of 10  $\mu$ l of 1N NaOH (LPCR, Strasbourg, France). Enzyme activity was measured at 405 nm in a microplate reader (Labsystem, France).

5 Acid phosphatase activity is proportional to the amount of living cells. The results were expressed as percentage O.D. as compared to control conditions (same 10 rinsing and medium replacements, but no intoxication and no treatment with either NGF, riluzol or the test compounds).

#### In Vivo Procedures

15 Animals received vincristine 0.15 mg/ml (IP) per day with the following timing: 5 days of intoxication followed with 2 days without vincristine injection and a new period of 5 days of intox followed with 2 days no intoxication and 2 other days of intoxication with vincristine followed by a 3 week recovery period. The test compound was administered daily from the first day of vincristine injection to the end of the experiments

20 Subjects used were 65 female Dark Agouti rats (200-250 g) (n = 13 per group). Five groups were used: (1) a vehicle control group; (2) a vincristine-vehicle group; (3) a vincristine + AIT-082 3 mg/kg IP group; (4) a vincristine + AIT-082 10 mg/kg IP group; and (5) a vincristine + AIT-082 30 mg/kg IP group.

25 *Behavioral measurements.* The general health and weight of animals were checked every day. Sensorimotor tests were performed twice a week during 6 week study, starting one week before beginning of intoxication (baseline).

30 *Electrophysiological measurements.* Electrophysiological recordings were performed once a week using a Neuromatic 2000M electromyographical apparatus (Dantec, France). EMG were performed under Ketamine anesthesia (Imalgène 500®, Mérieux, France).

The measured parameters were: the sensitive nerve conduction velocity (SNCV), the amplitude and the latency compound muscle action potential (CMAP).

*Sensitive nerve conduction velocity.* Skin electrodes were used. Caudal nerve was stimulated with a series of 20 pulses during 0.2 ms at a supramaximal intensity. The mean of 20 stimulations is included for statistical analysis.

*Compound muscle action potential and distal latency.* CPAM was measured in gastrocnemius muscle after stimulation of the sciatic nerve. Sciatic nerve was stimulated with a single 0.2 ms pulse at a supramaximal intensity (12.8 mA). The amplitude (mV) and the latency of the response (ms) are measured. The amplitude is 5 indicative of the number of active motor units, while distal latency reflects motor nerve conduction velocity.

*Drug administration.* The test compound was administered daily by the i.p. route from the first day of intoxication with the vincristine to the end of the experiments.

10 *Morphometric analysis.* The morphometric analysis was performed on 3 animals per group on sciatic nerve. It includes the measurements of various parameters according to the following procedure:

(1) Dissection of a segment of sciatic nerve (2 cm from the spinal cord, L5-L6, to the trifurcation of the sciatic).

15 The tissue was fixed overnight with glutaraldehyde 4% in phosphate buffer (PH 7.4) and then maintained in 30% sucrose in phosphate buffer at + 4°C until use. The sciatic nerve was fixed in 2% osmium tetroxide in phosphate buffer for 2 hours, dehydrated in serial alcohol solutions and embedded in Epon. Embedded tissues were then placed at +70°C for 3 days.

20 (2) Microtome sections : Transverse sections of 1.5 µm were made with a microtome and stained with toluidine blue, then dehydrated and mounted in Eurokitt.

(3) Morphometric analysis : Sections were observed using an optical microscope (Nikon) and morphometric analysis were performed with a semi-automated digital image analysis software (Morphonerf, Alcatel). Per slice, 4 fields 25 were analyzed, the number of myelinated fibers, density of fibers, diameter of fibers, thickness of myelin sheath, surface of myelin sheath and G factor.

## RESULTS

*In Vitro Results.* AIT-082 at a concentration of 1 µM significantly increased survival compared to cisplatin alone (Figure 1). These effects diminished 30 progressively with higher doses. Neotrofin was 10 times more potent than riluzole and had a greater effect than 5 ng/ml of NGF. AIT-034 was ineffective at all concentrations (0.01-100 µM).

*In Vivo Results.* Vincristine treatments (alone and with AIT-082) produced significant reductions in body weight with repetitive dosing compared to day matched

controls with vehicle treatment (Figure 2) at days 11-19 and 22-31. These effects all these treatments were reversible by the termination of treatments. This suggests that the dosage of vincristine and the route of administration did not induce permanent deterioration of health. AIT-082 in combination with vincristine produced a pattern of

5 dose-related reductions in body weight below that observed with control or vincristine alone. The body weights of the animals treated with AIT-082 at 30 mg/kg were significantly lower than treatment with vincristine alone at days 11, 14, 16, 18, 24 and 25. These effects were also reversible and did not appear to effect the improvements in sensory nerve conduction or EMG amplitude described below.

10 AIT-082 produced significant and dose-related changes in sensory nerve conduction velocity at day 17 during the initial phase of intoxication to vincristine and day 31 during the recovery phase of the study. These finding are suggestive that AIT-082 can lessen the severity of the neuropathy and increase the recovery to normal condition.

15 AIT-082 produced significant and dose-related changes in EMG amplitude at days 17 and 23 during the initial phase of intoxication to vincristine and days 31 and 38 during the recovery phase of the study. These finding are suggestive that AIT-082 can lessen the severity of the neuropathy and improve recovery. Although these data can not distinguish between effects on muscle responses and effects on nerve 20 conduction, they are supportive of the findings on sensory nerve conduction velocity.

At the end of the treatment periods, AIT-082 treatment was found to have produced greater numbers of myelinated nerve fibers in sciatic nerve biopsies than in animals treated with vincristine alone. These findings are also supportive of either a preventative or regenerative effect of AIT-082 on neurotoxicity induced by vincristine.

25 *DISCUSSION*

In an in vitro model for neurotoxicity induced by oncolytic drugs, AIT-082 produced statistically significant protection against cisplatin induced neurotoxicity. These findings indicate that AIT-082 given simultaneously to with an oncolytic drug in patients undergoing cancer therapy could prevent the neuropathic side-effects. 30 Further confirmation of this was obtained from an in vivo model for neurotoxicity induced by oncolytic drugs. In this model, AIT-082 treatment reduced the severity the vincristine induced changes in sensory nerve conduction velocity and electromyographic responses and improved the rate of recovery after the termination of vincristine therapy. The in vivo studies are supportive of a potential use of AIT-082

and related compounds for the prevention of drug-induced neuropathies and also suggest that these compounds could be used to improve recovery from these neuropathies.

*Clinical implications of the present findings.*

5 There is increasing evidence that deficient neurotrophic support, including that provided to cutaneous nerves by NGF, contributes to the pathogenesis of drug-induced neuropathies, such as oncolytic therapies. In animal studies, Hayakawa et al. 1998 demonstrated that NGF could prevent neurotoxicity induced by vincristine, taxol and cisplatin. In clinical studies, patients suffering from neurological deficits related to 10 treatments with antitumor agents have low circulating levels of NGF (De Santis et al., 2000).

*REFERENCES*

15 K. Hayakawa, T. Itoh, H. Niwa, T. Mutoh and G. Sobue, "NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: In vitro study of adult rat sympathetic ganglion explants. Brain Research 794:313-319 (1998)

20 S. De Santis, A. Pace, L. Bove, F. Cognetti, F. Properzi, M. Fiore, V. Triaca, A. Savarese, M. D. Simone, B. Jandolo, L. Manzione and I. Aloe. "Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of Nerve Growth Factor." Clinical Cancer Research 6: 90-95, 2000.

Further, indirect support for this therapeutic approach comes from our earlier findings (Diamond et al., 1988; 1992a) that chronic NGF-deprivation causes a shrinkage of nociceptive fields in the skin consistent with a "dying-back" neuropathy. AIT-082 administration, were it to induce endogenous NGF increases in the skin of 25 patients taking oncolytic drugs, could help protect NGF-sensitive neurons from the threat of neuropathy, without the hazard of hyperalgesia, as explained above.

*REFERENCES*

The following references are cited in Example 1:

30 Albers KM, Wright DE, Davis BM (1994) Overexpression of nerve growth factor in epidermis of transgenic mice causes hypertrophy of the peripheral nervous system. *J Neurosci* 14:1422-1432.

Campenot RB (1994) NGF and the local control of nerve terminal growth. *J Neurobiol* 25:599-611

Dantes M and McComas A (1981) The extent and time course of motoneuron involvement in amyotrophic lateral sclerosis. *Muscle and Nerve* 14:416-421.

Davis BM, Fundin BT, Albers KM, Goodness TP, Cronk KM, Rice FL (1997) Overexpression of nerve growth factor in skin causes preferential increases among 5 innervation to specific sensory targets. *J Comp Neurol* 387:489-506

Diamond J, Cooper G and Turner C (1976) Trophic regulation of nerve sprouting. *Science* 193:371-377.

Diamond J, Holmes M and Visheau B (1988) NGF-regulated plasticity in the adult nervous system. *Soc Neurosci Abstr* 14:245.6

10 Diamond J, Coughlin M, MacIntyre L, Holmes M and Visheau B (1987) Evidence that endogenous nerve growth factor is responsible for the collateral sprouting, but not regeneration, of nociceptive axons in adult rats. *Proc Natl Acad Sci USA* 84:6596-6600.

Diamond J, Coughlin M and Holmes M (1992a) Endogenous NGF and impulses 15 regulate the collateral sprouting of sensory nerves in the skin of the adult rat. *J. Neurosci* 12:1454-1466.

Diamond J, Holmes M, Foerster A and Coughlin M (1992b) Sensory nerves in adult rats regenerate and restore sensory function to the skin independently of endogenous NGF. *J. Neurosci* 12:1467-1476.

20 Doucette R, Diamond J (1987) The normal and precocious sprouting of heat nociceptors in the skin of adult rats. *J. Comp. Neurol* 261:592-603.

English KB, Harper S, Stayner N, Wang ZM, Davies AM (1994) Localization of nerve growth factor (NGF) and low-affinity NGF receptors in touch domes and quantification of NGF mRNA in keratinocytes of adult rats. *J. Comp. Neurol* 344:470-25 480.

Gloster A, Diamond J (1992) Sympathetic nerves in adult rats regenerate normally and restore pilomotor function during an anti-NGF treatment that prevents their collateral sprouting. *J. Comp. Neurol* 326:363-374.

Imayarna S (1981) Scanning and transmission electron microscope study on 30 the terminal blood vessels of the rat skin. *J. Invest Dermatol* 76:151-157.

Jackson PC, Diamond J (1984) Temporal and spatial constraints on the collateral sprouting of low-threshold mechanosensory nerves in the skin of rats. *J. Comp. Neurol* 226:336-345.

Karchewski LA, Kim FA, Johnston J, McKnight RM, Verge VM (1999) Anatomical evidence supporting the potential for modulation by multiple neurotrophins in the majority of adult lumbar sensory neurons. *J Comp Neurol* 413(2):327-41.

Korschning S, Theonen H (1985) Nerve growth factor supply for sensory 5 neurons: site of origin and competition with the sympathetic nervous system. *Neurosci Lett* 54:201-205.

Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. 1996 Nerve growth factor: from neurotrophin to neurokine. *TINS* 19:514-520.

Lewin GR, Ritter AM, Mendell LM (1993) Nerve growth factor-induced 10 hyperalgesia in the neonatal and adult rat. *J. Neurosci* 13:2136-2148.

Lewin GR, Rueff A, Mendell LM (1994) Peripheral and central mechanisms of NGF-induced hyperalgesia. *Eur J Neurosci* 6:1903-1912.

Mearow KM, Kril Y, and Diamond J (1993) Increased NGF mRNA expression in denervated rat skin. *Neuroreport* 4:351-354.

Murphy RA, Acheson A, Hodges R, Haskins J, Richards C, Reklow E V, Chlumecky V, Barker PA, Alderson RF, Lindsay RM (1993) Immunological 15 relationships of NGF, BDNF and NT3; recognition and functional inhibition by antibodies to NGF. *J. Neurosci* 13:2853-2862.

Neumann S, Doubell TP, Leslie T, Woolf CJ. 1996 Inflammatory pain 20 hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. *Nature* 384:360-364.

Nixon BJ, Doucette R, Jackson P and Diamond J (1984) Impulse activity evokes precocious sprouting of nociceptive nerves into denervated skin. *Somatosensory Res* 2:97-126.

Pertens E, Urschel-Gybers BA, Holmes M, Pal R, Foerster A, Kril Y and Diamond J (1999) Intraspinal and behavioural consequences of NGF-induced 25 nociceptive sprouting and NGF induced hyperalgesia compared in adult rats. *J Comp Neurol* 410:73-89.

Ramer MS, Kawaja MD, Henderson JT, Roder JC, Bisby MA (1998) Glial 30 overexpression of NGF enhances neuropathic pain and adrenergic sprouting into DRG following sciatic nerve constriction in mice. *Neurosci Lett* 251 53-56

Romero MI, Rangappa N, Li L, Lightfoot E, Garry MG, Smith GM (2000) Extensive sprouting of sensory afferents and hyperalgesia induced by conditional expression of nerve growth factor in the adult spinal cord. *J Neurosci* 20:4435-4445

Stucky CL, Koltzenburg M, Schneider M, Engle MG, Albers KM, Davis BM (1999) Overexpression of nerve growth factor in skin selectively affects the survival and functional properties of nociceptors. *J Neurosci* 19:8509-8516

5 Theriault E, Diamond J (1988) Nociceptive cutaneous stimuli evoke localized contractions in a skeletal muscle. *J Neurophysiol* 60:446-462.

Toma JG, Rogers D, Senger DI, Campenot RB, Miller FD (1997) Spatial regulation of neuronal gene expression in response to nerve growth factor. *Dev Biol* 184: 1-9

10 Yasargil GM, Macintyre L, Doucette R, Visheau B, Holmes M and Diamond J (1988) Axonal domains within shared touch domes in the rat: a comparison of their fate during conditions favoring collateral sprouting and following axonal regeneration. *J Comp Neurol* 270:301-312.

EXAMPLE 2

FURTHER NEUROPROTECTIVE EFFECTS OF AIT-082

15 The objectives of the studies described in this application are to evaluate AIT-082 and related analogues for their potential utility in the treatment of neuropathies associated with oncolytic therapies. The prototypic compound, AIT-082, is currently in Phase 2 clinical trials for Alzheimer's disease (AD) and has been proven safe in over 1400 patients. Its preclinical pharmacological effects include neuroprotection against 20 excitotoxicity, induction of the synthesis and secretion of neurotrophic and pleiotrophic factors, neuroregenerative effects and proliferative effects on neural progenitor cells. The effects of AIT-082 are unlike any product that has been approved or is currently under evaluation for neuropathies associated with oncolytic agents. AIT-082 and its second generation analogues may arrest or retard neurodegenerative processes, 25 promote neuroregeneration and provide symptomatic relief for cancer patients with neuropathies or at high risk of developing neuropathies.

**Background:** AIT-082 (Neotrofin™, Iteprinim potassium, 4[[3(1,6-dihydro-6-oxo-9-purin-9-yl)-1-oxopropyl] amino] benzoic acid, potassium salt) is a novel therapeutic agent currently in clinical testing for the treatment of AD. The proposed 30 preclinical studies and clinical trials for AIT-082 in oncolytic therapy-induced neuropathies are based upon its neuroprotective, neurotrophic and neuroregenerative effects in preclinical research. These effects may prevent or reverse the progressive degenerative changes associated with oncolytic therapies.

**In vitro effects on expression and secretion of nerve growth factors:**

Modulation of the secretion or efficacy of neurotrophic factors may have a major role in preventing or reversing neuropathies due to oncolytic therapies<sup>3,4</sup>. Findings from studies with rat astrocyte cultures provided evidence that AIT-082 increases the

5 production of mRNAs for several neurotrophic factors, including NGF, basic fibroblast growth factor (bFGF), and neurotrophin 3 (NT-3)<sup>1,2</sup>. In astrocytes, AIT-082 enhanced the secretion into the culture medium of the neurotrophic proteins NGF, TGF and S 100<sup>5</sup>. The secretion of NGF and TGF were dependent upon *de novo* protein synthesis induced by AIT-082 as indicated by the suppression of these effects by cycloheximide  
10 pre-treatment. The secretion of S 100 was independent of protein synthesis and from existing cellular stores after AIT-082 treatment.

**In vivo effects on expression and secretion of nerve growth factors:** In attempt to further explore the effects of AIT-082 that could be beneficial for chemotherapy-induced neuropathy, additional studies were conducted on dose-  
15 related effects on BDNF levels in the spinal cord. In these studies, AIT-082 was administered in drinking water for 7 days and BDNF content was measured by ELISA assay. AIT-082 produced significant dose-related increases in BDNF levels in the rat spinal cord.

The following are the references for Example 2:

20 1. Glasky AJ, Glasky MS, Ritzmann RF and Rathbone MP. AIT-082, a novel purine derivative with neuroregenerative properties. *Exp. Opin. Invest. Drugs.* 6:1413-1417, 1997.

25 2. Rathbone MP, Middlemiss PJ, Gysbers J, Diamond J, Holmes M, Pertens E, Juurlink BH, Glasky A, Ritzmann R, Glasky M, Crocker CE, Ramirez JJ, Lorenzen A, Fein T, Schultze E, Schwabe U, Cicarelli R, Di Iorio P, and Caciagli F. Physiology and pharmacology of natural and synthetic nonadenine-based purines in the nervous system. *Drug. Devel. Res.* 45:356-372, 1998.

30 3. Hayakawa K, Sobue G, Itoh T. Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. *Life Sci* 55:591-525, 1994.

4. Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G, NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. *Brain Res* 794:313-319, 1998.

5. Middlemiss P, Glasky AJ, Rathbone MP, Werstuik E, Hindley S and Gysbers J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated outgrowth from PC12 cells. *Neurosci. Letters* 199:1-4, 1995.

#### **ADVANTAGES OF THE INVENTION**

5 The present invention provides new methods for treating patients with drug-induced peripheral neuropathy, including peripheral neuropathy associated with the administration of oncolytic drugs, to induce peripheral nerve sprouting, which can include nociceptive nerve sprouting. These methods provide for nerve regeneration. These methods can be performed, at least in some alternatives, without inducing 10 hyperalgesia. These methods can be combined with other treatments for drug-induced peripheral neuropathy, such as palliative measures for the relief of pain. They do not depend on specific interactions between the compounds administered and the drugs causing peripheral neuropathy.

15 Although the present invention has been described in considerable detail, with reference to certain preferred versions thereof, other versions and embodiments are possible. Therefore, the scope of the invention is determined by the following claims.

**WE CLAIM:**

1. A method of treating drug-induced neuropathy comprising administering to a patient with drug-induced neuropathy an effective amount of a compound having activity against drug-induced neuropathy, the compound comprising: (1) a moiety A selected from the group consisting of a purine moiety, a purine analogue, a tetrahydroindolone moiety, a tetrahydroindolone analogue, a pyrimidine moiety, and a pyrimidine analogue; (2) a hydrocarbyl moiety L of 1 to 6 carbon atoms that is linked to the moiety A and that can be cyclic, with the hydrocarbyl moiety being optionally substituted with one or more substituents selected from the group consisting of lower alkyl, amino, hydroxy, lower alkoxy, lower alkylamino, lower alkylthio, and oxo; and (3) a moiety B that is linked to the moiety L wherein B is  $-OZ$  or  $N(Y_1)-D$ , where Z is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, aralkyl, or heteroaralkyl; D is a moiety that promotes absorption of the compound having activity against drug-induced neuropathy; and  $Y_1$  is hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms, which can be N, O, or S.


2. The method of claim 1 wherein the compound having activity against drug-induced neuropathy passes through the blood-brain barrier.

3. The method of claim 1 wherein A is a purine moiety.


4. The method of claim 3 wherein A is a substituted or unsubstituted hypoxanthine moiety.

5. The method of claim 4 wherein L has the structure  $-(CH_2)_n-CONH-$  where n is an integer from 1 to 6.

6. The method of claim 5 wherein the compound having activity against drug-induced neuropathy is a compound of formula (I)



where n is an integer from 1 to 6 and R is hydrogen or lower alkyl or is a salt or prodrug ester of a compound of formula (I)



wherein n is an integer from 1 to 6 and R is hydrogen or lower alkyl.

7. The method of claim 6 wherein the compound having activity against drug-induced neuropathy is a compound of formula (I) wherein n is an integer from 1 to 6 and R is hydrogen or lower alkyl.


8. The method of claim 7 wherein R is hydrogen.

9. The method of claim 8 wherein n is 2 and the compound is N-4-[[3-(1,6-dihydro-6-oxo-purin-9-yl)-1-oxopropyl] amino] benzoic acid.

10. The method of claim 7 wherein R is ethyl.


11. The method of claim 10 wherein n is 2 and the compound is N-4-[[3-(1,6-dihydro-6-oxo-purin-9-yl)-1-oxopropyl] amino] benzoic acid ethyl ester.

12. The method of claim 5 wherein the compound having activity against drug-induced neuropathy is a compound of formula (II)




wherein n is an integer from 1 to 6, R is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, wherein W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, and R<sub>2</sub> is selected from the group consisting of H and OH.

13. The method of claim 12 wherein n is 2.
14. The method of claim 5 wherein the compound having activity against drug-induced neuropathy is a compound of formula (III)



wherein n is an integer from 1 to 6, R<sub>1</sub> is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, wherein W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, R<sub>2</sub> is selected from the group consisting of H and OH, and R<sub>3</sub> is selected from the group consisting from the group consisting of H and OH.

15. The method of claim 14 wherein n is 2.
16. The method of claim 3 wherein A is a substituted or unsubstituted guanine moiety.
17. The method of claim 16 wherein L has the structure -(CH<sub>2</sub>)<sub>n</sub>-CONH- wherein n is an integer from 1 to 6.
18. The method of claim 17 wherein the compound having activity against drug-induced neuropathy is a compound of formula (IV)




wherein n is an integer from 1 to 6,  $R_1$  is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, wherein W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino and  $R_2$  is selected from the group consisting of H and OH.

19. The method of claim 18 wherein n is 2,  $R_1$  is H, and  $R_2$  is OH, and the compound is N-(2-(5-hydroxyindol-3-yl)) ethyl-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

20. The method of claim 18 wherein n is 2,  $R_1$  is H, and  $R_2$  is H, and the compound is N-(2-(2-indol-3-yl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

21. The method of claim 18 wherein n is 2,  $R_1$  is COOH, and  $R_2$  is OH, and the compound is N-(1-carboxyl-(2-(5-hydroxyindol-3-yl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

22. The method of claim 17 wherein the compound having activity against drug-induced neuropathy is a compound of formula (V)




wherein n is an integer from 1 to 6 and R is selected from the group consisting of hydrogen and lower alkyl.

23. The method of claim 22 wherein n is 2, R is hydrogen, and the compound is N-4-carboxyphenyl-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

24. The method of claim 22 wherein n is 2, R is ethyl, and the compound is N-4-carboxyphenyl-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide ethyl ester.

25. The method of claim 17 wherein the compound having activity against drug-induced neuropathy is a compound of formula (VI)




wherein n is an integer from 1 to 6 and R is selected from the group consisting of hydrogen and lower alkyl.

26. The method of claim 25 wherein n is 2, R is hydrogen, and the compound is 3-(2-amino-6-oxohypoxanthine-9-yl) propanoic acid.

27. The method of claim 25 wherein n is 2, R is ethyl, and the compound is 3-(2-amino-6-oxohypoxanthine-9-yl) propanoic acid ethyl ester.


28. The method of claim 17 wherein the compound having activity against drug-induced neuropathy is a compound of formula (VII)



wherein n is an integer from 1 to 6, p is an integer from 1 to 6, and q is an integer from 1 to 3.

29. The method of claim 28 wherein n is 2, p is 2, and q is 1, and the compound is N-[2-[2-(2-oxopyrrolidin-1-yl)-1-oxoethyl] amino] ethyl] propanamide.

30. The method of claim 17 wherein the compound having activity against drug-induced neuropathy is a compound of formula (VIII)




wherein n is an integer from 1 to 6, R<sub>1</sub> is selected from the group consisting of H, COOH, and COOW<sub>1</sub>, wherein W<sub>1</sub> is selected from the group consisting of lower alkyl, amino, and lower alkylamino, R<sub>2</sub> is selected from the group consisting of H and OH, and R<sub>3</sub> is selected from the group consisting of H and OH.

31. The method of claim 30 wherein n is 2, R<sub>1</sub> is H, R<sub>2</sub> is H, and R<sub>3</sub> is OH, and the compound is N-(2-(3,4-dihydroxyphenyl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

32. The method of claim 30 wherein n is 2, R<sub>1</sub> is H, R<sub>2</sub> is OH, and R<sub>3</sub> is OH, and the compound is N-(2-hydroxy-2-(3,4-dihydroxyphenyl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

33. The method of claim 30 wherein n is 2, R<sub>1</sub> is COOH, R<sub>2</sub> is H, and R<sub>3</sub> is H, and the compound is N-(1-carboxyl-2-(3,4-dihydroxyphenyl)ethyl)-3-(2-amino-6-oxohypoxanthine-9-yl) propanamide.

34. The method of claim 16 wherein the compound having activity against drug-induced neuropathy is a compound of formula (IX)




wherein n is an integer from 1 to 6 and p is an integer from 1 to 3.

35. The method of claim 34 wherein n is 2, p is 1, and the compound is N-4[[3-(2-amino-6-oxohypoxanthine-9-yl) 1-oxopropyl] amino] benzoic acid 1-(dimethylamino)-2-propyl ester.

36. The method of claim 1 wherein A is a substituted or unsubstituted 9-atom bicyclic moiety in which the 5-membered ring has 1 to 3 nitrogen atoms, the

bicyclic moiety having the structure of formula (X)



where:

- (a) if the bond between N<sub>1</sub> and the bond between C<sub>5</sub> is a single bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a double bond, R<sub>6</sub> is O or S, and R<sub>1</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, or heteroaralkyl;
- (b) if the bond between N<sub>1</sub> and C<sub>6</sub> is a double bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a single bond, R<sub>1</sub> is not present, and R<sub>6</sub> is hydrogen, halo, amino, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;
- (c) if the bond between C<sub>2</sub> and N<sub>3</sub> is a single bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a double bond, R<sub>2</sub> is O or S, and R<sub>3</sub> is hydrogen or alkyl;
- (d) if the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond, then the bond between C<sub>2</sub> is a single bond, R<sub>3</sub> is not present, and R<sub>2</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo, amino, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>,

where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_1$  and  $Q_2$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(e)  $A_7$  and  $A_8$  are C or N;

(i) if  $A_7$  and  $A_8$  are both C and the bond between  $A_7$  and  $A_8$  is a single bond, then the bond between  $A_8$  and  $R_8$  is two single bonds to two hydrogen atoms or is a double bond in which  $R_8$  is O or S and  $R_7$  is two hydrogen atoms;

(ii) if  $A_7$  and  $A_8$  are both C and the bond between  $A_7$  and  $A_8$  is a double bond, then  $R_7$  is hydrogen, the bond between  $A_8$  and  $R_8$  is a single bond and  $R_8$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;

(iii) if  $A_7$  and  $A_8$  are both N, then the bond between  $A_7$  and  $A_8$  is a double bond, and  $R_7$  and  $R_8$  are not present;


(iv) if  $A_7$  is C and  $A_8$  is N, then the bond between  $A_7$  and  $A_8$  is a double bond,  $R_7$  is hydrogen, and  $R_8$  is not present;

(v) if  $A_7$  is N,  $A_8$  is C, and the bond between  $A_7$  and  $A_8$  is a double bond, then  $R_7$  is not present, the bond between  $A_8$  is a single bond, and  $R_8$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;

(vi) if  $A_7$  is N,  $A_8$  is C, and the bond between  $A_7$  and  $A_8$  is a single bond, then  $R_7$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, the bond between  $A_8$  and  $R_8$  is a double bond, and  $R_8$  is O or S; and

(f)  $N_9$  is bonded to L; with the proviso that A does not have the structure of an unsubstituted guanine or hypoxanthine.

37. The method of claim 3 wherein the purine moiety is a purine moiety of formula (XI)



in which:

(a)  $R_1$  is selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, and heteroaralkyl; and  $R_2$  is selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo,  $OQ_1$ ,  $SQ_1$ ,  $NHNH_2$ ,  $NHOQ_1$ ,  $NQ_1Q_2$ , or  $NHQ_1$ , where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_1$  and  $Q_2$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, arylkoxycarbonyl, heteroarylokoxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroarylalkylaminocarbonyl in which the alkyl portions could be cyclic and can contain from one to three heteroatoms which could be N, O, or S, with the proviso that both  $R_1$  and  $R_2$  are not hydrogen and that  $R_1$  is not hydrogen when  $R_2$  is amino.

38. The method of claim 37 wherein  $R_1$  is butyl and  $R_2$  is hydrogen.
39. The method of claim 37 wherein  $R_1$  is benzyl and  $R_2$  is hydrogen.
40. The method of claim 37 wherein  $R_1$  is dimethylaminoethyl and  $R_2$  is hydrogen.
41. The method of claim 37 wherein  $R_1$  is cyclopentyl and  $R_2$  is hydrogen.

42. The method of claim 37 wherein R<sub>1</sub> is cyclohexylmethyl and R<sub>2</sub> is hydrogen.

43. The method of claim 37 wherein R<sub>1</sub> is cyclopropylmethyl and R<sub>2</sub> is hydrogen.

44. The method of claim 37 wherein R<sub>1</sub> is hydrogen and R<sub>2</sub> is phenyl.


45. The method of claim 37 wherein R<sub>1</sub> is hydrogen and R<sub>2</sub> is butyl.

46. The method of claim 37 wherein R<sub>1</sub> is butyl and R<sub>2</sub> is butyl.

47. The method of claim 37 wherein R<sub>1</sub> is hydrogen and R<sub>2</sub> is methyl.

48. The method of claim 37 wherein R<sub>1</sub> is hydrogen and R<sub>2</sub> is phenylamino.

49. The method of claim 3 wherein the purine moiety is a purine moiety of Formula (XII)




in which:

(a) R<sub>2</sub> is selected from the group consisting of hydrogen, halo, amino, OQ<sub>3</sub>, SQ<sub>3</sub>, NHNH<sub>2</sub>, NHOQ<sub>3</sub>, NQ<sub>3</sub>Q<sub>4</sub>, or NHQ<sub>3</sub>, where Q<sub>3</sub> and Q<sub>4</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>3</sub> and Q<sub>4</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>3</sub> where Y<sub>3</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S; and

(b)  $R_6$  is selected from the group consisting of hydrogen, halo, amino,  $OQ_5$ ,  $SQ_5$ ,  $NHNH_2$ ,  $NHOQ_5$ ,  $NQ_5Q_6$ , or  $NHQ_6$ , where  $Q_5$  and  $Q_6$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, and heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_5$  and  $Q_6$  are present together and are alkyl, they can be taken together to form a 5- or 6- membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, arylkoxycarbonyl, heteroarylkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S.

50. The method of claim 49 wherein  $R_2$  is hydrogen and  $R_6$  is amino.
51. The method of claim 49 wherein  $R_6$  is chloro.
52. The method of claim 49 wherein  $R_6$  is phenylamino.
53. The method of claim 49 wherein  $R_2$  is amino and  $R_6$  is chloro.
54. The method of claim 3 wherein the purine moiety is the purine moiety of Formula (XIII)



in which:


- (a)  $R_1$  is hydrogen, alkyl, aralkyl, cycloalkyl, or heteroaralkyl; and
- (b)  $R_2$  is O or S.
55. The method of claim 54 wherein  $R_1$  is hydrogen.
56. The method of claim 54 wherein  $R_2$  is O.

57. The method of claim 54 wherein  $R_2$  is S.
58. The method of claim 3 wherein the compound is 4-[3-(1-benzyl-6-oxo-1,6-dihdropurin-9-yl)propionylamino] benzoic acid ethyl ester.
59. The method of claim 3 wherein the compound is 4-[3-(1-butyl-6-oxo-1,6-dihdropurin-9-yl)propionylamino] benzoic acid ethyl ester.
60. The method of claim 3 wherein the compound is 4-[3-(1-methyl-6-oxo-1,6-dihdropurin-9-yl)propionylamino] benzoic acid ethyl ester.
61. The method of claim 3 wherein the compound is 4-[3-(1-2-dimethylaminoethyl)-6-oxo-1,6-dihdropurin-9-yl) propionylamino] benzoic acid ethyl ester.
62. The method of claim 3 wherein the compound is 4-[3-(2,6-dioxo-1,2,3,6-tetrahydropurin-9-yl) propionylamino] benzoic acid ethyl ester.
63. The method of claim 3 wherein the compound is 4-[3-(6-methoxypurin-9-yl) propionylamino] benzoic acid ethyl ester.
64. The method of claim 3 wherein the compound is 4-[3-(6-dimethylaminopurin-9-yl) propionylamino] benzoic acid ethyl ester.
65. The method of claim 3 wherein the compound is 4-[3-(2-amino-6-chloropurin-9-yl) propionylamino] benzoic acid ethyl ester.
66. The method of claim 3 wherein the compound is 4-[2-(6-oxo-2-thioxo-1,2,3,6-tetrahydropurin-9-yl) propionylamino] benzoic acid ethyl ester.
67. The method of claim 3 wherein the compound is 4-[2-(2-butyl-6-oxo-1,6-dihdropurin-9-yl) propionylamino] benzoic acid ethyl ester.
68. The method of claim 3 wherein the compound is 4-[2-(6-oxo-2-phenyl-1,6-dihdropurin-9-yl) propionylamino] benzoic acid ethyl ester.
69. The method of claim 3 wherein the compound is 4-{{3-(6-chloropurin-9-yl) propionyl} methylamino} benzoic acid methyl ester.
70. The method of claim 3 wherein the compound is 3-(1-benzyl-6-oxo-1,6-dihdropurin-9-yl)-N-[3-(2-oxopyrrolidin-1-yl)propyl] propanamide.
71. The method of claim 3 wherein the compound is 3-(1-benzyl-6-oxo-1,6-dihdropurin-9-yl)-N-{2-[2-(2-oxopyrrolidin-1-yl)acetylamino]ethyl} propanamide.

72. The method of claim 3 wherein the compound is N-[3-(2-oxopyrrolidin-1-yl)propyl]-3-(6-oxo-2-thioxo-1,2,3,6-tetrahydropurin-9-yl) propanamide.

73. The method of claim 3 wherein the compound is 3-(1-benzyl-6-oxo-1,6-dihydropurin-9-yl)-N-(3-morpholin-4-yl)propyl propionamide.

74. The method of claim 1 wherein the compound is a tetrahydroindolone derivative or analogue where A is a 9-atom bicyclic moiety in which the 5-membered ring has one to three nitrogen atoms, the bicyclic moiety of Formula (XIV)



where:

- (a)  $N_1$  is bonded to L;
- (b)  $A_2$  and  $A_3$  are C or N;
  - (i) If  $A_2$  and  $A_3$  are both C and the bond between  $A_2$  and  $A_3$  is a single bond, then the bond between  $A_2$  and  $R_2$  is two single bonds, two hydrogen atoms or is a double bond in which  $R_2$  is O or S and  $R_3$  is two hydrogen atoms;
  - (ii) If  $A_2$  and  $A_3$  are both C and the bond between  $A_2$  and  $A_3$  is a double bond, then  $R_3$  is hydrogen, the bond between  $A_2$  and  $R_2$  is a single bond and  $R_2$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;
  - (iii) If  $A_2$  and  $A_3$  are both N, then the bond between  $A_2$  and  $A_3$  is a double bond and  $R_2$  and  $R_3$  are not present;
  - (iv) If  $A_2$  is N and  $A_3$  is C, then the bond between  $A_2$  and  $A_3$  is a double bond,  $R_2$  is not present, and  $R_3$  is hydrogen;
  - (v) If  $A_2$  is C,  $A_3$  is N, and the bond between  $A_2$  and  $A_3$  is a double bond, then  $R_3$  is not present, the bond between  $A_2$  and  $R_2$  is a single bond, and  $R_2$  is hydrogen, halo, alkyl, alkenyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, or heteroaralkenyl;

(vi) If  $A_2$  is C,  $A_3$  is N, and the bond between  $A_2$  and  $A_3$  is a single bond, then  $R_3$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, or heteroaralkenyl, the bond between  $A_2$  and  $R_2$  is a double bond, and  $A_2$  is O or S;

(c)  $R_5$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,  $NH_2$ ,  $NHQ_1$ ,  $NQ_1Q_2$ , OH,  $OQ_1$ , or  $SQ_1$ , where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when  $Q_1$  and  $Q_2$  are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom, which can be N, O, or S, of which the N can be further substituted with  $Y_2$ , where  $Y_2$  is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(d)  $R_5'$  is hydrogen unless  $R_5$  is alkyl, in which case  $R_5$  is hydrogen or the same alkyl as  $R_5$ ;

(e)  $R_5$  and  $R_5'$  can be taken together as a double bond to  $C_5$ , and can be O, S,  $NQ_3$ , or C which can be substituted with one or two groups  $R_5$ , where  $Q_3$  is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

(f)  $R_6$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl,  $NH_2$ ,  $NHQ_4$ ,  $NQ_4Q_5$ , OH,  $OQ_4$ , or  $SQ_4$ , where  $Q_4$  and  $Q_5$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl,

alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>4</sub> and Q<sub>5</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom, which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;


(g) R<sub>6'</sub> is hydrogen unless R<sub>6</sub> is alkyl, in which case R<sub>6'</sub> is hydrogen or the same alkyl as R<sub>6</sub>;

(h) R<sub>6</sub> and R<sub>6'</sub> can be taken together as a double bond to C<sub>6</sub> and can be O, S, NQ<sub>6</sub>, or C which can be substituted with one or two groups R<sub>5</sub>, and where Q<sub>6</sub> is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S; and

(i) R<sub>7</sub> is hydrogen unless R<sub>5</sub> is alkyl and R<sub>5'</sub> is hydrogen, in which case R<sub>7</sub> is the same alkyl as R<sub>5</sub>.

75. The method of claim 74 wherein A is a tetrahydroindolone moiety.

76. The method of claim 75 wherein the tetrahydroindolone moiety is a tetrahydroindolone moiety of formula (XV)



in which:

(a)  $R_5$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,  $NH_2$ ,  $NH_1$ ,  $NQ_1Q_2$ , OH,  $OQ_1$ , or  $SQ_1$ , where  $Q_1$  and  $Q_2$  are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be cyclic and can contain from one to three heteroatoms which can be N, O, or S;

(b)  $R_5$  is hydrogen;

(c)  $R_6$  is hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl,  $NH_2$ ,  $NHW_1$ ,  $NQ_1Q_2$ , OH,  $OQ_1$ , or  $SQ_1$ , where  $Q_1$  and  $Q_2$  are aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be cyclic and can contain from one to three heteroatoms which can be N, O, or S and where  $W_1$  is alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from one to three heteroatoms which can be N, O, or S;

(d)  $R$  is hydrogen; and


(e)  $R_7$  is hydrogen.

77. The method of claim 76 wherein  $R_5$ ,  $R_5'$ ,  $R_6$ ,  $R_6'$ , and  $R_7$  are all hydrogen.

78. The method of claim 77 wherein the compound is 4-[3-(4-oxo-4,5,6,7-tetrahydroindolon-1-yl) propionylamino] benzoic acid ethyl ester.

79. The method of claim 77 wherein the compound is 4-[3-(4-oxo-4,5,6,7-tetrahydroindolon-1-yl) propionylamino] benzoic acid.

80. The method of claim 1 wherein A is an amino-substituted 6-membered heterocyclic moiety of formula (XVI)



where:

- (a) if the bond between N<sub>1</sub> and the bond between C<sub>6</sub> is a single bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a double bond, R<sub>6</sub> is O or S, and R<sub>1</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, or heteroaralkyl;
- (b) if the bond between N<sub>1</sub> and C<sub>6</sub> is a double bond, then the bond between C<sub>6</sub> and R<sub>6</sub> is a single bond, R<sub>1</sub> is not present, and R<sub>6</sub> is hydrogen, halo, amino, OH, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;
- (c) if the bond between C<sub>2</sub> and N<sub>3</sub> is a single bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a double bond, R<sub>2</sub> is O or S, and R<sub>3</sub> is hydrogen or alkyl;
- (d) if the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond, then the bond between C<sub>2</sub> and R<sub>2</sub> is a single bond, R<sub>3</sub> is not present, and R<sub>2</sub> is hydrogen, alkyl, aralkyl, cycloalkyl, heteroaralkyl, halo, amino, OH, OQ<sub>1</sub>, SQ<sub>1</sub>, NHNH<sub>2</sub>, NHOQ<sub>1</sub>, NQ<sub>1</sub>Q<sub>2</sub>, or NHQ<sub>1</sub>, where Q<sub>1</sub> and Q<sub>2</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl,

aryol, aralkanoyl, heteroaralkanoyl, heteroaroyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, or heteroaralkylsulfonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>1</sub> and Q<sub>2</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>3</sub>, where Y<sub>3</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S;

- (e) R<sub>4</sub> is hydrogen, alkyl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl;
- (f) A<sub>5</sub> is carbon or nitrogen;
- (g) if A<sub>5</sub> is nitrogen, then R<sub>5</sub> is not present;
- (h) if A<sub>5</sub> is carbon, then R<sub>5</sub> is hydrogen, amino, alkyl, alkoxy, halo, nitro, aryl, cyano, alkenyl, or alkaryl;
- (i) if R<sub>5</sub> and R<sub>6</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, aralkoxycarbonyl, heteroaralkoxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S; and
- (j) N<sub>4</sub> is bonded to L.

81. The method of claim 80 wherein A<sub>5</sub> is carbon and the 6-membered heterocyclic moiety is a pyrimidine moiety.

82. The method of claim 81 wherein R<sub>2</sub> is O and R<sub>3</sub> is hydrogen.

83. The method of claim 82 wherein the pyrimidine moiety is selected from the group consisting of cytosine, thymine, uracil, 3-methyluracil, 3-methylthymine, 4-methylcytosine, 5-methylcytosine, 5-hydroxymethylcytosine, 5-hydroxyuracil, 5-carboxymethyluracil, and 5-hydroxymethyluracil.

84. The method of claim 81 wherein R<sub>2</sub> is S and R<sub>3</sub> is hydrogen.

85. The method of claim 84 wherein the pyrimidine moiety is selected from the group consisting of 2-thiouracil, 5-methylamino-2-thiouracil, 5-methyl-2-thiouracil, 2-thiocytosine.

86. The method of claim 81 wherein R<sub>2</sub> is amino and the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond.

87. The method of claim 86 wherein the pyrimidine moiety is selected from the group consisting of 2-aminopyrimidinone and 2-amino-4-chloropyrimidine.

88. The method of claim 81 wherein R<sub>2</sub> is hydrogen and the bond between C<sub>2</sub> and N<sub>3</sub> is a double bond.

89. The method of claim 88 wherein the pyrimidine moiety is selected from the group consisting of 4-chloropyrimidine, 5-amino-4-chloropyrimidine, 4-chloro-5-methylpyrimidine, 4-chloro-5-hydroxymethylpyrimidine, and 4-chloro-5-carboxymethylpyrimidine.

90. The method of claim 81 wherein R<sub>1</sub> is hydrogen, methyl, or ethyl, R<sub>5</sub> is hydrogen, methyl, or ethyl, and R<sub>6</sub> is O.

91. The method of claim 90 wherein the pyrimidine moiety is pyrimidinone.

92. The method of claim 81 wherein the compound is 4-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

93. The method of claim 81 wherein the compound is 4-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

94. The method of claim 81 wherein the compound is 4-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

95. The method of claim 81 wherein the compound is 4-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

96. The method of claim 81 wherein the compound is 4-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

97. The method of claim 81 wherein the compound is 4-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

98. The method of claim 81 wherein the compound is 3-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

99. The method of claim 81 wherein the compound is 3-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

100. The method of claim 81 wherein the compound is 3-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid ethyl ester.

101. The method of claim 81 wherein the compound is 3-[3-(2-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

102. The method of claim 81 wherein the compound is 3-[3-(6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

103. The method of claim 81 wherein the compound is 3-[3-(5-amino-6-chloropyrimidin-4-ylamino) propionylamino] benzoic acid.

104. The method of claim 1 wherein L has the structure  $-(CH_2)_n-$  wherein n is an integer from 1 to 6.

105. The method of claim 104 wherein n is 2.

106. The method of claim 104 wherein n is 3.

107. The method of claim 1 wherein the moiety B is  $-OZ$ .

108. The method of claim 107 wherein Z is hydrogen.

109. The method of claim 107 wherein Z is alkyl.

110. The method of claim 109 wherein Z is selected from the group consisting of methyl, ethyl, butyl, propyl, and isopropyl.

111. The method of claim 1 wherein B is  $-N(Y_1)-D$ .


112. The method of claim 111 wherein  $Y_1$  is hydrogen.

113. The method of claim 111 wherein  $Y_1$  is lower alkyl.

114. The method of claim 113 wherein  $Y_1$  is methyl.

115. The method of claim 111 wherein D is a moiety having at least one polar, charged, or hydrogen-bond-forming group to increase the water-solubility of the compound.

116. The method of claim 115 wherein D is a carboxylic acid or carboxylic acid ester with the structure




wherein p is an integer from 1 to 6 and  $W_1$  is selected from the group consisting of hydrogen and lower alkyl.

117. The method of claim 116 wherein  $W_1$  is hydrogen.


118. The method of claim 116 wherein  $W_1$  is ethyl.

119. The method of claim 115 wherein D and  $Y_1$  are taken together to form a piperazine derivative of the structure



wherein  $Q_1$  is hydrogen, methyl, ethyl, butyl, or propyl, and  $Q_2$  is hydrogen or methyl, where, if  $Q_2$  is methyl, it can be located on either of the two possible positions in the piperazine ring.


120. The method of claim 115 wherein D has the structure



wherein one of  $Z_1$  and  $Z_2$  is hydrogen and the other is  $Z_1$  and  $Z_2$  is  $-\text{COOH}$  or  $-\text{COOW}_1$ , wherein  $W_1$  is alkyl.


121. The method of claim 120 wherein  $W_1$  is selected from the group consisting of methyl, ethyl, propyl, butyl, and isobutyl.

122. The method of claim 115 wherein D is a phenylsulfonamidyl moiety of the structure




wherein p is an integer from 0 to 6.

123. The method of claim 115 wherein D is an alkylpyridyl moiety of the structure



wherein p is an integer from 1 to 6.

124. The method of claim 114 wherein D is an dialkylaminoalkyl moiety of the structure



wherein p is an integer from 1 to 6 and Q<sub>7</sub> and Q<sub>8</sub> are alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, alkanoyl, aroyl, aralkanoyl, heteroaralkanoyl, or heteroaroyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S, and when Q<sub>7</sub> and Q<sub>8</sub> are present together and are alkyl, they can be taken together to form a 5- or 6-membered ring which can contain one other heteroatom which can be N, O, or S, of which the N can be further substituted with Y<sub>2</sub>, where Y<sub>2</sub> is alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, alkanoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, aralkylsulfonyl, heteroaralkylsulfonyl, alkoxy carbonyl, aryloxy carbonyl, heteroaryloxy carbonyl, aralkoxy carbonyl, heteroaralkoxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, aralkylaminocarbonyl, or heteroaralkylaminocarbonyl, in which the alkyl portions can be cyclic and can contain from 1 to 3 heteroatoms which can be N, O, or S.

125. The method of claim 124 wherein Q<sub>7</sub> and Q<sub>8</sub> are each alkyl.

126. The method of claim 125 wherein Q<sub>7</sub> and Q<sub>8</sub> are each selected from the group consisting of methyl, ethyl, propyl, butyl, and isobutyl.

127. The method of claim 126 wherein Q<sub>7</sub> and Q<sub>8</sub> are taken together to form 5- or 6-membered optionally substituted ring.

128. The method of claim 127 wherein the ring is a morpholinyl ring.

129. The method of claim 127 wherein the ring is a pyrrolidinyl ring that is optionally substituted with oxo.

130. The method of claim 126 wherein the ring is a piperidinyl ring that is optionally substituted with methyl or ethyl.

131. The method of claim 115 wherein D is an alkylpyrrolidinyl moiety of the structure

wherein p is an integer from 1 to 6 and W<sub>1</sub> is selected from the group consisting of methyl, ethyl, and propyl.

132. The method of claim 1 wherein the compound has a log P of from about 1 to about 4.

133. The method of claim 1 wherein the action of the compound having activity against drug-induced neuropathy is to induce upregulation of neurotrophic factor synthesis.

134. The method of claim 133 wherein the neurotrophic factor is selected from the group consisting of NGF, NT-3, BDNF, and NT-4/5.

135. The method of claim 1 wherein the administration of the compound having activity against drug-induced neuropathy induces peripheral nerve sprouting in the skin of the patient to whom the compound was administered.

136. The method of claim 135 wherein the peripheral nerve sprouting is nociceptive nerve sprouting.

137. The method of claim 136 wherein the nociceptive nerve sprouting is induced without the occurrence of hyperalgesia.

138. The method of claim 1 wherein the drug-induced neuropathy is induced by the administration of an oncolytic drug.

139. The method of claim 138 wherein the oncolytic drug is selected from the group consisting of a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine,

carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, and thioguanine.

140. The method of claim 139 wherein the oncolytic drug is vincristine.
141. The method of claim 139 wherein the oncolytic drug is paclitaxel.
142. The method of claim 139 wherein the oncolytic drug is cisplatin.

1/3




FIG. 1




FIG. 2

2/3

**Sensory Nerve Conduction Velocity**  
**Effects of AIT-082 on Vincristine-Induced Neuropathy**




FIG. 3

**EMG Amplitude**  
**Effects of AIT-082 on Vincristine-Induced Neuropathy**




FIG. 4

3/3




FIG. 5

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number  
WO 02/004448 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/52,  
31/405, 31/505

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/US01/21373

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 6 July 2001 (06.07.2001)

(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data: 60/216,844 7 July 2000 (07.07.2000) US

(71) Applicant (for all designated States except US):  
NEOTHERAPEUTICS, INC. [US/US]; 157 Technology Drive, Irvine, CA 92618 (US).

Published:

— with international search report

(72) Inventors; and  
(75) Inventors/Applicants (for US only): DIAMOND, Jack [CA/CA]; 25 Chedoke Avenue Lane, Hamilton, Ontario L8P 4S1 (CA). GLASKY, Alvin, J. [US/US]; 11955 Lambert, Tustin, CA 92782 (US).

(88) Date of publication of the international search report:  
23 January 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(74) Agents: CULLMAN, Louis, C. et al.; Oppenheimer Wolff & Donnelly LLP, Suite 700, 840 Newport Center Drive, Newport Beach, CA 92660-7007 (US).

WO 02/004448 A3

(54) Title: METHODS FOR TREATMENT OF DRUG-INDUCED PERIPHERAL NEUROPATHY AND RELATED CONDITIONS

(57) Abstract: A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidine derivative or analogue. If the compound is a purine derivative, the purine moiety can be guanine or hypoxanthine. The compound can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy associated with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. Methods according to the present invention are particularly useful in treating peripheral neuropathy associated with the administration of vincristine, paclitaxel, or cisplatin.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/21373

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/52 A61K31/405 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**CHEM ABS Data, BEILSTEIN Data, BIOSIS, EPO-Internal, PAJ, WPI Data**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 03125 A ( A.J. GLASKY) 8 February 1996 (1996-02-08)	1-4,6-9, 111,112, 115,120, 133,134
Y	page 19, line 26 - page 20, line 9; examples 2, 12, 29; claims 15, 16 and 31 idem	1-15, 107-116, 120-131, 133,134, 138-142
	----	-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

13 May 2002

8. 08. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Van Amsterdam, L

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/US 01/21373

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91 14434 A (A.J. GLASKY) 3 October 1991 (1991-10-03)  page 7, lines 30-35; page 42, lines 15-18; pages 44-59 idem	1-15, 107-116, 120-131  36, 37
Y	WO 97 33572 A (SOMERSET PHARMACEUTICALS INC) 18 September 1997 (1997-09-18)  page 5, line 16 - page 6, line 17, page 7, line 17 - page 8, line 8 ---	1,133, 134, 138-142
A	M.P. RATHBONE ET AL: DRUG DEVELOPMENT RESEARCH, vol. 45, no. 3-4, 1998, pages 356-372, XP000904784  page 363, column 1, lines 26-29; page 367, column 2, line 36 - page 368, column 1, line 42 ---	1-4,6-9, 111,112, 115,120, 133-137
A	B.R. BAKER ET AL: J. PHARM. SCI., vol. 54, no. 11, 1965, pages 1609-1616, XP001076681  table I, compounds XV, XVIII; scheme I, compounds XVI, XXII-XXVII, XXIX ---	1,3,36, 49-51, 107,108, 111,112, 115-117, 120,121
A	B.R. BAKER ET AL: J. PHARM. SCI., vol. 54, no. 12, 1965, pages 1774-1781, XP001076680  table 1, compounds VIII, XXVI, XXVII ---	1,3,36, 107,108, 111,112, 115,120
A	WO 96 20711 A (UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER) 11 July 1996 (1996-07-11)  page 3, lines 1-23; page 4, lines 14-29; page 5, line 25; page 8, lines 24-32 ---	1,3,16, 36,37, 48,107, 108
P,X	M. HOLMES ET AL: SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, XP001040388  abstract no. 511.9	1-4,6-9, 111,112, 115,120, 133-137
P,O,X	& 30th Annual Meeting of the Society of Neuroscience; New Orleans, US; November 04-09 2000 ---	
		-/-

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/21373

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 01 29039 A (NEOTHERAPEUTICS INC) 26 April 2001 (2001-04-26)  whole document, in particular formulae I-VII, X, XIII-XIV, XVIII, XXVI-XXVII, XXX, XXXII, XXXV, XL, and page 31, line 26 - page 32, line 13 idem	1-3, 16-35, 107,108, 111,112, 115-117, 120-131, 133,134  36,37
A		
P,A	WO 00 32197 A (ALCON LABORATORIES INC) 8 June 2000 (2000-06-08)  page 7; claims 1-3, 8-10 -----	1-4,6-9, 111,112, 115,120, 133,134

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/21373

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**Although claims 1-142 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.**
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**1-2, 104-142 (in part); 3-73**

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-2, 104-142 (in part); 3-73

Compounds of the formula A-L-B of claim 1, wherein A is selected from the group consisting of a purine moiety and a purine analogue, for use in treating peripheral neuropathy.

2. Claims: 1-2, 104-142 (in part); 74-79

Compounds of the formula A-L-B of claim 1, wherein A is selected from the group consisting of a tetrahydroindolone moiety and a tetrahydroindolone analogue, for use in treating peripheral neuropathy.

3. Claims: 1-2, 104-142 (in part); 80-103

Compounds of the formula A-L-B of claim 1, wherein A is selected from the group consisting of a pyrimidine moiety and a pyrimidine analogue, for use in treating peripheral neuropathy.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1 and 36 relate to extremely large numbers of possible compounds for use in the treatment of peripheral neuropathy. In fact, the claims contain so many variables and options that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be sufficiently clear and concise, namely those parts relating to compounds of formula A-L-B of claim 1, wherein

A is a substituted or unsubstituted purine moiety covered by formula X of claim 36 for A7 is N and A8 is C and having any of the structures of formulae XI, XII or XIII (see claims 37, 49 or 54, respectively), an unsubstituted hypoxanthine moiety (see claim 4) or an unsubstituted guanine moiety (see claim 16),

L is a -(C1-6 straight or branched chain alkylene)-C(0)- linking group (see claims 6, 12, 14, 18, 22, 25, 28, 30, 34, 58-73) attached to N9 of the purine, hypoxanthine or guanine moiety (see claim 36, page 42, (f)), and

B is -OZ wherein Z is hydrogen or alkyl (see claims 108-110), or -N(Y1)-D wherein Y1 is hydrogen or alkyl (see claims 112-114) and D is as defined in claims 116-131 or is any of the D groups present in the compounds of claims 6, 12, 14, 18, 22, 25, 28, 30, 34, 58-73.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 01/21373

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9603125	A 08-02-1996	US	5447939 A	05-09-1995
		US	5801184 A	01-09-1998
		AU	709454 B2	26-08-1999
		AU	3277595 A	22-02-1996
		BR	9508339 A	30-09-1997
		CA	2195302 A1	08-02-1996
		CZ	9603802 A3	14-01-1998
		EP	0772440 A1	14-05-1997
		FI	970302 A	24-01-1997
		HU	76294 A2	28-07-1997
		JP	10504814 T	12-05-1998
		NO	970312 A	27-01-1997
		NZ	291592 A	30-03-2001
		PL	318293 A1	09-06-1997
		US	6027936 A	22-02-2000
		WO	9603125 A1	08-02-1996
		US	6338963 B1	15-01-2002
		US	6350752 B1	26-02-2002
-----	-----	-----	-----	-----
WO 9114434	A 03-10-1991	US	5091432 A	25-02-1992
		AT	154880 T	15-07-1997
		AU	7678191 A	21-10-1991
		CA	2079342 A1	29-09-1991
		CS	9100859 A3	19-02-1992
		DE	69126701 D1	07-08-1997
		DE	69126701 T2	04-12-1997
		DK	522082 T3	21-07-1997
		EP	0522082 A1	13-01-1993
		ES	2104700 T3	16-10-1997
		GR	3024904 T3	30-01-1998
		IE	910994 A1	09-10-1991
		IL	97638 A	12-03-1999
		JP	3198335 B2	13-08-2001
		JP	5508390 T	25-11-1993
		NZ	237574 A	27-09-1993
		WO	9114434 A1	03-10-1991
-----	-----	-----	-----	-----
WO 9733572	A 18-09-1997	AU	709323 B2	26-08-1999
		AU	2339797 A	01-10-1997
		CA	2244253 A1	18-09-1997
		CN	1213300 A	07-04-1999
		EP	0906090 A1	07-04-1999
		JP	3258027 B2	18-02-2002
		JP	11507951 T	13-07-1999
		WO	9733572 A1	18-09-1997
		US	6239181 B1	29-05-2001
		US	2001023260 A1	20-09-2001
-----	-----	-----	-----	-----
WO 9620711	A 11-07-1996	US	5646155 A	08-07-1997
		AU	4688696 A	24-07-1996
		EP	0794781 A1	17-09-1997
		JP	10511952 T	17-11-1998
		WO	9620711 A1	11-07-1996
-----	-----	-----	-----	-----
WO 0129039	A 26-04-2001	US	6297226 B1	02-10-2001
		AU	1200401 A	30-04-2001
		NO	20021750 A	05-06-2002
		WO	0129039 A1	26-04-2001

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 01/21373

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
WO 0032197	A 08-06-2000	AU BR CN EP WO	3106600 A 9915803 A 1325308 T 1135134 A1 0032197 A1		19-06-2000 21-08-2001 05-12-2001 26-09-2001 08-06-2000